Duquesne University

Duquesne Scholarship Collection
Electronic Theses and Dissertations
Spring 2005

Structural and Functional Modifications of Human Serum Albumin
by Lipid Peroxidation By-Products
Amy Pollock

Follow this and additional works at: https://dsc.duq.edu/etd

Recommended Citation
Pollock, A. (2005). Structural and Functional Modifications of Human Serum Albumin by Lipid
Peroxidation By-Products (Doctoral dissertation, Duquesne University). Retrieved from
https://dsc.duq.edu/etd/1055

This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne
Scholarship Collection.

STRUCTURAL AND FUNCTIONAL MODIFICATION OF
HUMAN SERUM ALBUMIN BY LIPID PEROXIDATION
BY-PRODUCTS

A Dissertation Presented to the
Bayer School of Natural and Environmental Sciences
Duquesne University

In Partial Fulfillment for the
Degree of Doctor of Philosophy

By:

Amy M. Pollock
December 20, 2004

All Rights Reserved
© 2004
Amy M. Pollock

ii

Abstract
By-products of lipid peroxidation, specifically α,β-unsaturated aldehydes, are known to
modify nucleophilic amino acid residues, including lysine residues, in proteins. The
produced α,β-unsaturated aldehydes are stable enough to migrate from their site of
origin, therefore allowing them to come in contact with a wide range of biomolecules in
the system. Human serum albumin (HSA) is the most abundant plasma protein. It
contains 58 lysine residues that are distributed throughout the sequence and tertiary
structure of the protein, several of which are surface exposed. The research presented
herein explores the possibility that HSA provides an outlet of consumption for the α,βunsaturated aldehydes thereby eliminating the harmful lipid peroxidation by-products
from the system. The main objective of this research was to examine the structural and
functional modifications of HSA when it acts as a potential “sink” for the lipid
peroxidation by-products. Structural modifications were studied by investigating the
susceptibility of HSA to be modified by α,β-unsaturated aldehydes as characterized
through time course experiments. The functional modifications were investigated
through the impact of modified HSA to bind fatty acids or surrogate molecules.
Additionally, isothermal titration calorimetry was used to determine if modification would
compromise the ability of HSA to bind copper, therefore diminishing the antioxidant
capacity of HSA by allowing an increase of free copper in the system. Results from
these experiments will be discussed and conclusions made about the effect of
modification on the structure and function of HSA.
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Chapter 1: Introduction

1.1 Lipid Peroxidation
Lipid peroxidation is either a causative or an associative factor in various pathological
conditions, such as atherosclerosis, macular degeneration, ischemia-reperfusion injury,
tumorigenesis, and a variety of nervous disorders that results from the oxidative
deterioration of polyunsaturated fatty acids [1, 2]. Lipid peroxidation begins with a free
radical mechanism that yields lipid hydroperoxides as the major reaction products [3].
The lipid hydroperoxides then decompose to products that have a wide range of
damaging effects, including various α,β-unsaturated aldehydes as end products [3].
Pryor and Porter [4] have proposed a scheme for the production of one α,β-unsaturated
aldehyde, 4-hydroxy-2-nonenal (4HNE), from the autoxidation of polyunsaturated fatty
acids (Figure 1.1). The α,β-unsaturated aldehydes are relatively stable and therefore
can migrate to other regions in the system to react with molecules not directly adjacent
to the location where they were generated [5]. Even though these α,β-unsaturated
aldehydes are end products of lipid peroxidation, they are free to react with other
biomolecules present in the system.
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Figure 1.1: Suggested scheme for the production of 4-hydroxy-2nonenal from the autoxidation of arachidonic acid. Figure 1.1
reproduced from Pryor and Porter [4].

One of the consequences of lipid peroxidation is the age-related accumulation of
lipofuscin and ceroid in biological samples [2, 6]. Lipofuscion pigments isolated from
the human brain have been shown to have two different excitation/emission ranges, the
first around 390/450-470 nm and the other at 360/430 nm [2]. The longer wavelength is
characteristic of malondialdehyde adducts formed on lysine residues while the shorter
of the two excitation wavelengths is representative of lysine residue modification by 2alkenals [2]. Incubation of low density lipoprotein (LDL) with 4HNE in vitro produces
fluorescence identical to that found in oxidized LDL, having an excitation maximum at

2

360nm and emission maximum at 430nm [7]. The fluorescence inducing reaction that
occurs between 2-alkenals and lysine residues has also been shown to induce protein
cross-linking [8, 9].

1.2 Characterization of the Fluorescent Adduct
In an attempt to characterize the fluorescent compound(s) produced from the reaction of
lipid peroxidation products and biomolecules, several groups have used α,βunsaturated aldehydes and small molecules to mimic the in vivo reaction. Sayre et al.
[10] described the reaction between 4HNE and primary amines to form pyrroles as the
major product under physiomimetic pH 7.8 conditions. They proposed a mechanism
involving the initial formation of a Schiff base followed by a Paal-Knoor condensation
that was consistent with their results [10]. It was also noted that there were other
plausible mechanisms that would explain the multiple products observed from their
reaction [10].

Modification of apolipoprotein B found in LDL by E-2-octenal, a lipid peroxidation byproduct, caused a significant loss of histidine and lysine residues from the protein [11].
In an attempt to identify the structure of the modified lysine residue, E-2-octenal was
allowed to react with a lysine analog, N2-(carbobenzyloxy)-L-lysine. The reaction
products were characterized and determined to be quaternary pyridinium salts (Figure
1.2) [11]. Similar quaternary pyridinium adducts were isolated from the reaction of Nacetyl-glycyl-lysine methyl ester with E-2-hexenal [12]. These model studies, however,
did not represent cross-linked species and did not have fluorescent properties like those

3

observed with lipofuscin and ceroid. Compounds with fluorescence of excitation 360nm
and emission 430nm were generated from the reaction of primary amines with saturated
aldehydes in the presence of hydrogen peroxide [13]. One of these products, 2hydroxy-1,2-dihyrdopyrrol-3-one, was identified and represents non-cross linked protein
modifications [13].

O
-O

R

+

N

Figure 1.2: 1-(N2-(carbobenzyloxy)-L-lysyl)-2-(3’-carboxy-2’-E-propen1’-yl)-4-pentylpyridinium betaine, one of the quaternary pyridinium salts
produced from the reaction of E-2-octenal with N2-(carbobenzyloxy)-Llysine [11].

Through the use of NMR and mass spectral data, Nadkarni and Sayre [14] were able to
identify the first adducts formed from the reaction of n-butylamine with 4HNE. They
were able to isolate a 1:2 (4HNE:amine) adduct that existed as a cyclic hemiaminal
(Figure 1.3), representative of a stable lysine based cross-link which would be stable in
nonpolar protein microenvironments [14]. This structure is believed to be the result of a
Schiff base formation followed by Michael addition of two lysine side chain nucleophiles.
However, the pathway for the formation for the structure shown in Figure 1.2 is opposite
what was proposed by Uchida and Stadtman [15]. Using the reaction between
glyceraldehyde-3-phosphate dehydrogenase and 4HNE, Uchida and Stadtman were
able to identify three types of modification on the enzyme: (a) the aldehyde group from
4

4HNE reacts directly with the lysine amino group to form a Schiff base, (b) the 4HNE
double bond can react with the sulfhydryl, histidyl, or amino group to form a Michael
addition adduct, or (c) the aldehyde from the Michael addition adduct can undergo a
second reaction with another lysine group to form either intramolecular or intermolecular
cross-links [15]. Nadkarni and Sayre also isolated a 1:1 hemiacetal Michael adduct that
was shown to be the major product formed in aqueous environments (Figure 1.4) [14].
Both of the proposed adducts (either the hemiaminal or hemiacetal) are formed
reversibly and will revert back to the amine in neutral aqueous buffer without
stabilization by NaBH4 [2].

H9C4HN

H11C5

NHC4H9

O

Figure 1.3: Proposed structure of the cross-link formed from a 1:2
(4HNE:amine) Schiff base formation followed by a Michael addition [14].

H9C4HN

H11C5

O

OH

Figure 1.4: Proposed structure of the 1:1 (4HNE:amine) adduct formed
from Michael addition in an aqueous environment [14].

Xu and Sayre [2] reported the structure of a model lysine-lysine protein cross-link that
has an excitation of 360nm and emission of 430nm from the reaction of n-butylamine
with 4HNE. In contrast to earlier reports [6, 14], Xu and Sayre [2] proposed that the
Schiff base condensation at the C1 carbonyl would lead to the formation of a 2pentlypyrrole, which would lead to either the formation of pyrrole or the fluorophore.

5

The yield of the product (Figure 1.5) was much higher when n-butylamine was
incubated with 4-oxo-2-nonenal (4ONE) or 3,4-dioxononenal than with 4HNE [2].

+

NHBu
OH
C5H11

N
H

Figure 1.5: Proposed structure of fluorophore generated from the
reaction of n-butylamine with 4HNE [2].

Itakura et al. [16] reported a structural characterization of a 4HNE derived fluorescent
compound from the reaction of 4HNE with Nα-hippuryllysine. The fluorophore that
Itakura et al. [16] identified (Figure 1.6) was very similar in structure to that proposed by
Xu and Sayre [2] from a reaction with a different lysine-containing small molecule
(Figure 1.5). Around the same time that Itakura et al. [16] published their structure, Tsai
et al. [17] published a structure that they characterized from the reaction of 4HNE and
Nα-acetyllysine (Figure 1.7). This structure is also fluorescent and is formed from the
oxidative cyclization of the nonfluorescent 2:1 lysine-4HNE Michael adduct-Schiff base
cross-link [17].

6

R2
N
R1

N

HO

R2
Figure 1.6: 4HNE-lysine adduct isolated and characterized by Itakura et
al. [16], R1 = (CH2)4CH3 and R2 = (CH2)4CH(CO2H)NHCOCH2NHBz.
This adduct has fluorescence properties that are similar to those
observed in peroxidized systems.

HO2C

CH

NHCO2CH3

(CH2)4
N
H11C5
HO

N
(CH2)4

HO2C

CH

NHCO2CH3

Figure 1.7: 4HNE-lysine adduct isolated and characterized by Tsai et al.
[17].

Many of the α,β-unsaturated aldehydes produced via lipid peroxidation have been
shown to react with lysine side chains. Lipid peroxidation produces a variety of α,βunsaturated aldehydes that are free to react with other molecules in the system.
Specifically, 4-hydroxy-2-nonenal (4HNE), malondialdehyde (MDA) and various 2alkenals have been shown to react with lysine residues to form fluorescent proteins [2,
8, 16, 17]. The mechanism for fluorescence development is believed to involve a
combination of Michael addition and Schiff base formation using a lysine to aldehyde
ratio of 2:1 followed by two oxidation steps and cyclization [16]. In addition to lysine,
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other amino acid residues (Cys, His, and Arg) have been identified as being modified by
lipid peroxidation by-products [7, 14, 18-20].

1.3 Studies of Lipid Peroxidation By-Products
In addition to human and bovine serum albumins, there are hosts of other biomolecules
whose reaction with a variety of α,β-unsaturated aldehydes have been studied.
Specifically, DNA bases and several proteins and enzymes have been shown to react
with products of lipid peroxidation in order to form fluorescent products and cross-linked
species.

1.3.1 E-2-alkenals
The most commonly studied E-2-alkenals are E-2-hexenal (Figure 1.8a) and E-2octenal (Figure 1.8b). Both of these aldehydes have been shown to react with a variety
of species. Modification of histidine residues in proteins has been accepted to involve a
Michael addition of the imidazole nitrogen from the histidine to the α,β-unsaturated bond
of a 2-alkenal [11]. Apolipoprotein B from low density lipoprotein was modified by E-2octenal and the result was a significant loss of histidine and lysine residues in the
protein [11].

(a)

(b)

O

O

Figure 1.8: Structure of E-2-hexenal (a) and E-2-octenal (b).
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Alaiz and Barragán [8] report that changes are induced in bovine serum albumin (BSA)
upon incubation with E-2-octenal. From their work, fluorescence was produced in BSA
with an excitation maximum at 350 nm and an emission maximum at 440 nm [8]. Amino
acid analysis was used to determine that incubation of BSA with E-2-octenal lead to the
loss of lysine residues and the gain of new amino acid derivatives [8]. These same
fluorescent properties were seen upon incubation of N2-(carbobenzyloxy)-L-lysine with
E-2-octenal [8]. This also validated the hypothesis that the lysine residues in BSA were
important targets of modification. In addition to the development of fluorescence, they
also observed different SDS-PAGE patterns for unmodified and E-2-octenal modified
BSA [8]. Alaiz and Barragán [8] reported that the modified BSA migrated to five distinct
bands on the SDS gel; one band at 67kDA and the other four bands at higher
molelcular weights that represent cross-linked BSA. However, the authors did not
specify the molecular weights of the cross-linked species that they observed. It was
therefore only possible to estimate the molecular weights of the species that they
observed. Analysis of Alaiz and Barragán’s SDS gel [8] gave bands with molecular
weights of 66, 142, 192, and 245 kDa. The fifth band that Alaiz and Barragán reported
was not visible on the gel image in the publication. The higher molecular weight bands
approximately correspond to the molecular weights of the monomer, dimer (132kDa),
trimer (198kDa), and tetramer (264kDa) of BSA. The lane with unmodified BSA in the
gel did not exhibit any of the higher molecular weight species.

In an earlier study, Alaiz and Girón [21] found that the imidazole nitrogen from histidine
residues is the major target for reaction with E-2-octenal. They again incubated BSA,
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N-(carbobenzoxy)-L-histidine or poly(L-histidine) with E-2-octenal. Analysis of the
BSA/aldehyde incubation mixture after acid hydrolysis using HPLC revealed a loss of
the histidine residues compared to native BSA [21]. Reaction of N-(carbobenzoxy)-Lhistidine or poly(L-histidine) with E-2-octenal and analysis using HPLC revealed the
formation of a new compound that the authors claim corresponds to the E-2-octenalhistidine adducts [21]. They proposed that the adduct was formed through a Michael
addition which had been proposed previously by other groups using similar systems [19,
21].

Using the work of Alaiz et al. as a starting point, Zídek et al. [9] studied the changes
induced in horse heart cytochrome c upon incubation with E-2-hexenal. Cytochrome c
lacks free sulfhydryls, so the expected locations for reaction with E-2-hexenal are the
side chains of the19 lysine residues or the 3 histidine residues per molecule of protein.
Circular dichroism was used to confirm that there were no significant conformation
changes in cytochrome c during the reaction with E-2-hexenal [9]. Electrospray
ionization mass spectrometry was then used to confirm the presence of signals that
correspond to Schiff-base modification of the protein. After the E-2-hexenal was
removed from the protein by ultrafiltration, the signals that corresponded to Schiff-basemodified protein vanished and the signal due to unmodified protein was recovered [9].
However, the signals due to the Michael adducts remained visible [9]. Fluorescence
also developed at wavelengths similar to those observed when florescent derivatives
associated with lipid peroxidation are present [9]. The location of the hexenal-modified
amino acid residues was investigated through the use of trypsin and chymotrypsin
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digested protein separated on a reversed-phase capillary column. Due to the lack of
information generated by this method, MALDI-TOF-MS was then used to compare the
signals of hexenal-modified versus unmodified cytochrome c peptides [9]. Because of
the amino acid composition of the fragments, it was not possible for the exact location of
modification to be determined. However, comparison of the possible modification sites
with the molecular weights of the peptides indicates that nonspecific modification occurs
in at least half of the possible target residues [9]. The authors predict that the 19 lysine
residues and 3 histidine residues are the most reactive residues towards lipid
peroxidation by-products [9]. SDS-PAGE was also implemented to observe the
formation of cytochrome c dimmers and trimers (probably covalently cross-linked) upon
incubation with E-2-hexenal [9]. The studies of Zídek et al. [9] have set precedence for
modification of other proteins found in the body as a result of modification with lipid
peroxidation products.

1.3.2 4-Hydroxy-2-nonenal
4-Hydroxy-2-nonenal (HNE) (Figure 1.9) is one of the α,β-unsaturated aldehydes
produced from ω-6 polyunsaturated oxidation and has been identified as the “most
cytoxic aldehyde” produced by the body [7]. It has been shown that levels of less than
1µM 4HNE are present in the system and at these levels, 4HNE acts as a signaling
molecule [7]. During oxidative stress, 4HNE can be produced uncontrollably and will
saturate the pathways for metabolism allowing the excess 4HNE to modify biological
molecules [22]. In aqueous solutions, 4HNE is known to react with Cys, His, and Lys
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residues through a Michael addition to form a hemiacetal which then rearranges to a
cyclic hemiacetal [7, 14, 19].

O

OH

Figure 1.9: Structure of 4-hydroxy-2-nonenal (4HNE).

HNE can be produced in the laboratory through various procedures. The most common
procedure reacts the Grignard compound of propynal diethylacetal with hexanal to form
4-hydroxy-2-nonynal diethylacetal [7]. The triple bond is then converted to the trans
double bond and the resulting 4-hydroxy-2-nonenal diehtylacetal is hydrolyzed to the
free acid, 4-hydroxy-2-nonenal [7]. This procedure can also be applied to other nalkenals with different chain lengths to produce a variety of 4-hydroxyalkenals [7].

Pryor and Porter [4] proposed a possible mechanism for the formation of 4HNE from
ω6-polyunsaturated fatty acids (Figure 1.1). Experimental evidence for the formation of
4HNE from fatty acid hydroperoxides was given by Gardner and Hamberg [23]. They
showed that Z-3-nonenal could be converted to 4-hydroperoxy-2E-nonenal by a 3Zalkenal oxygenase [23]. Recently, Schneider et al. [24] have proposed a mechanism for
the production of HNE from the 9- and 13-hydroperoxides of linoleic acid. They found
two distinct mechanisms lead to the formation of 4-hydroperoxy-2E-nonenal that could
then be converted to 4HNE [24]. Their proposed mechanism can also be applied to
other fatty acid hydroperoxides to form 4HNE.
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Studies have indicated that 4HNE is reactive towards the amino acids Cys, His, and Lys
[7, 20]. The order of reactivity towards these amino acid residues in short polypeptides
was determined to be Cys p His > Lys [20]. Although Cys is the most reactive amino
residue based on rate constants, the adduct formed may be the least stable [25]. This
is because of the reversibility of the 4HNE-thiol adduct [22]. It is possible that Cys
residues are the intended target for biological signaling, however, when excess 4HNE is
present (for example, under oxidative stress), the concentration of 4HNE would be high
enough to react with other residues (His and Lys) to produce more stable adducts [22].

The cellular effects of 4HNE depend on the ability of a cell to metabolize 4HNE [7].
Several enzymes (mitochondrial aldehyde dehydrogenase, aldehyde reductase, aldose
reductase, and glutathione-S-transferase) have been shown to metabolize 4HNE to less
reactive substances therefore making 4HNE unable to react with and cause harm to
other biomolecules in the system [22].

Various enzymes have been shown to become inactive through modification with 4HNE.
Szweda et al. [26] studied the inactivation of glucose-6-phosphate dehydrogenase by
4HNE. The loss of enzyme activity was accompanied by the modification of a lysine
residue in the glucose-6-phosphate dehydrogenase active site to form a lysine-4HNE
adduct [26]. Friguet et al. [6] also studied glucose-6-phosphate dehydrogenase and
found that modification by 4HNE also leads to cross-links and the development of
protein-associated fluorescence. Glyceraldehyde-3-phosphate dehydrogenase
modified by 4HNE resulted in inactivation of the enzyme [15]. Amino acid analysis
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indicated that Cys, His, and Lys residues were modified by 4HNE and SDS-PAGE gels
of the modified enzyme indicate the formation of intramolecular and intermolecular
cross links [15]. Recently, Ishii et al. [27] followed the pathway of inactivation of
glyceraldehyde-3-phosphate dehydrogenase by 4HNE and used mass spectrometry to
identify the sites of modification. They modified the enzyme with 4HNE and digested it
with trypsin and V8 protease. Five peptides were identified that contained 4HNE
adducts at His-164, Cys-244, Cys-281, His-327, and Lys-331 [27]. Modification at the
active site (Cys-149) was not observed which indicated that inactivation of
glyceraldehyde-3-phospate dehydrogenase is due to modification of amino acids
located on the surface of the molecule [27]. Other enzymes that have been shown to
become inactivated by 4HNE include glutathione S-transferase, glutathione reducatse,
interlukin 1B converting enzyme, aldose reducatse, and bovine cathepsin B [25]. Plant
enzymes are also modified by 4HNE. Millar and Leaver [28] have identified 2oxogluterate dehydrogenase, pyruvate dehydrogenase complex and NAD-malic
enzyme all found in plant mitochondria are inhibited by 4HNE.

A variety of proteins have also been identified as targets for 4HNE modification. Human
low density lipoprotein (LDL) treated with 4HNE migrated with increased mobility on an
SDS-PAGE gel [29]. The increased mobility was the result of an increase in the
negative charge on apolipoprotein B. Epithelial fatty acid-binding protein is a target for
modification by 4HNE [30]. Apomyoglobin [31], bovine myoglobin [32], and GTP
binding protein [25] can also be modified by 4HNE.
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1.3.3 4-Oxo-2-Nonenal
4-Oxo-2-nonenal (4ONE) (Figure 1.10) has recently been identified as a major product
of lipid peroxidation [33]. An ω-6 lipid hydroperoxide, 13-hydroperoxy-linoleic acid,
undergoes Fe-mediated decomposition to produce 4ONE [33-35]. 4ONE was first
shown to induce modifications in free nucleobases and DNA [35]. The modified
structure formed was later found to be heptone-etheno adducts [36-38]. 4ONE is
structurally similar to 4HNE with the only difference being a ketone on carbon 4 instead
of an alcohol as in 4HNE. Doorn and Peterson have suggested that this substitution
makes 4ONE more reactive than 4HNE towards protein nucleophiles because the C4
ketone is an additional target for nucleophiles (especially amines) and hydration of the
aldehyde on 4HNE but not on 4ONE results in the loss of the α,β-unsaturated carbonyl
[20]. Loss of the α,β-unsaturated carbonyl makes the molecule unable to undergo
Michael addition. The Keq of hydration of ketones ranges from 10-4 to 10-2 [39]. This
means that the ketone at C4 will only be hydrated to a very small extent (less than 1%)
[20]. It has also been suggested that because 4ONE does not contain a hydroxyl group
it cannot cyclize and therefore can contain two free carbonyl groups that are reactive
towards primary amines [20].

O

O

Figure 1.10: Structure of 4-oxo-2-nonenal, 4ONE.

In a study of short-chained peptides ranging in length from 4 to 6 amino acid residues,
4ONE was found to modify peptides containing Arg, Cys, His, and Lys by forming a
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stable covalent adduct [20]. This study is particularly noteworthy because it is the first
time that reactivity of 4ONE towards amino acid nucleophiles has been detected [20].
They found that the order of reactivity towards the amino acids was Cys p His > Lys >
Arg [20]. Because these studies were done using small peptides, it is possible that the
same order of reactivity does not hold true for larger peptides and proteins. Matrixassisted laser desorption ionization - time of flight - mass spectrometry (MALDI-TOFMS) analysis was used to determine the molecular weight of the adduct, 156 Da for
4HNE modified peptide and 154 Da for 4ONE modified peptide. The molecular weights
for both adducts correspond to the masses expected from a Michael addition reaction.
This information indicated the presence of two carbonyl groups in the adduct formed
from 4ONE (Figure 1.11) [20]. Therefore, it is possible for each carbonyl of the 4ONE
modification to react with an amine, like Lys, which would result in extensive crosslinking of the protein [20].

O

O
Peptide/Protein

Figure 1.11: Proposed structure of the 4ONE peptide/protein adduct as
described by Doorn and Petersen [20]. Theoretically, the protein or
peptide can bind via Michael addition to either C2 or C3 and the adduct
structure should contain two free carbonyl groups.

In addition to forming oxidative cross-linking of amines, 4ONE has recently been shown
to form nonoxidative cross-linking of amines [40]. Model proteins, ribonuclease A and
β-lactoglobulin, were incubated with 4ONE, 4HNE, or 4DDE (trans, trans-2, 4decadienal) and very little protein cross-linking was observed in the absence of oxygen.
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However, Lys-Lys cross-linking was enhanced in the presence of oxygen with 4ONE
[40]. Cross-linking was also observed with 4HNE, but the extent of cross-linking was
not as great as that seen with 4ONE [40]. Cross-linking was eliminated when 4HNE,
4ONE, or 4DDE was incubated with ribonuclease A containing methylated Lys residues,
indicating that the lysine ε-groups are required for protein cross-linking [40].

4ONE shares at least one end product of protein modification with 4HNE, the lysinelysine cross-link [31]. 4ONE and 4HNE modification of myoglobin resulted in Michael
adducts on protein nucleophiles that were sometimes accompanied by dehydration as
observed using electrospray mass spectrometry [31]. Modification of 4ONE on
apomyoglobin followed by reduction and proteolysis gave 4 species that were identified
by mass spectrometry: 4ONE-histidine Michael adduct, 4ONE-lysine pyrrolinone
adduct, 4ONE-histidine-lysine pyrrole adduct, and an unidentified M + 166 lysine adduct
[31]. This was the first structural characterization of the Lys modification on an intact
protein by 4HNE or 4ONE using mass spectrometry [31].

Doorn et al. [41] have investigated whether reductive catalysis by aldose reductase is a
pathway for biotransformation of 4ONE. Kinetic data showed that aldose reductase
catalyzes the reduction of 4ONE with kcat = 92.2 min-1 and KM = 42.0 µM [41]. The
reduction 4ONE to 1,4-dihydroxynon-2-ene (DHN) makes it inert towards other
molecules in the system. They were also interested to see if 4ONE would react with
other nucleophiles close to the active site of aldose reductase. No enzymatic activity
was lost when aldose reductase was incubated with 4ONE in the presence of NADPH
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because the cofactor protects Cys 298, the most reactive amino acid residue for 4ONE
modification [41].

Oe et al. [42] studied the effects of 4ONE on the arginine-rich protein, bovine histone
4H. They were attempting to prove that modifications due to 4ONE were not only
restricted to cross-linking of proteins, but could also be modifications on amino acid
residues in a single protein. Through a series of 4ONE modifications and digestions by
CNBr and different proteases, the target for 4ONE modification was identified as the
amino acid sequence of histidine-alanine-lysine [42]. They believe that the modification
is the result of the imidazole ring (from the histidine) attaching to C3 of 4ONE followed
by lysine initiated pyrrole ring formation [42]. Oe et al. [42] further postulate that this
motif found in other histone proteins could also be susceptible to similar modification by
4ONE, altering the protein’s ability to function. In a separate study, the same group
investigated the structure of the adduct formed when arginine was modified by 4ONE
[43]. Arginine had been previously shown to be one of the amino acid residues
susceptible to 4ONE modification [20], however, the structure of the adduct had yet to
be determined. Because of the modification on the DNA base 2’-deoxyguanosine by
4ONE [35], they believed that the guanidine moiety would react with 4ONE in an
analogous manner. Oe et al. [43] reported the chemical structure of 4ONE modified
arginine as a cyclic carbinolamine adduct.
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1.4 Human Serum Albumin
1.4.1 Historical Significance
HSA has been studied for decades, with the earliest account being in 400 A.D. when
Hippocrates noted the presence of foam in the urine of people with renal disease [44].
A significant clinical use of albumin was recognized and applied during World War II,
when albumin was used as a stable substitute for blood plasma on the battlefield [44].
HSA could be used because methods were available in which it could be prepared as a
pure protein and made readily available. Since then, there have been many discoveries
related to the structure and function of this protein. The amount of research related to
all species of albumin is too vast to be described in detail here and the reader is
referred to All About Albumin by Theodore Peters, Jr. for a more comprehensive
description regarding the research related to this protein [44].

1.4.2 Structural Information
Human serum albumin (HSA) is the most abundant protein found in plasma with a
concentration of approximately 0.6 mM [45]. It is comprised of a single polypeptide
chain (585 amino acid residues) that consists of three domains made up of ~67% αhelical secondary structure and has a molecular weight of ~68 kDa (Figure 1.12). The
primary function of HSA is to transport fatty acids, but it also binds a wide range of
molecules as well as aiding in the maintenance of the pH and osmotic pressure of
plasma [46]. Under normal physiological conditions, 0.1 to 2 moles of fatty acid are
bound to HSA at any given time [47]. These fatty acids rapidly exchange between the
solution and the protein binding sites despite their capability for tight HSA binding [47].
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Figure 1.12: Human Serum Albumin (HSA) from the crystal structure of
Sugio et al. [48].

The three dimensional structure of human serum albumin was first reported at a
resolution of 2.8Å by He and Carter in 1992 [49]. They reported the structure of HSA to
be made up of three homologous domains (I, II, and III) [49]. Each domain contains ten
helices divided into two subdomains, subdomain A composed of six-helices and
subdomain B comprised of four-helices [50]. The helices in HSA orient themselves with
each other to form a heart-shaped molecule [49]. HSA is not a static molecule, but
rather is very flexible and rapidly changes its conformation in a “breathing” motion that
makes the protein capable of binding and releasing many of the molecules that it
transports [44]. In addition, several conformations of HSA have been observed under
nonphysiological conditions. Four isomers of normal (N) HSA have been observed [44].
The E (extended) form exists below pH 3, the F (fast) form at pH 4, the B (basic) form
near pH 8, and the A (aged) form near pH 10 [44]. The F form has been described as
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having an extended tertiary structure as compared to the normal form of HSA. As the
pH is decreased, the tertiary structure continues to relax until it is as fully extended as
allowed by the disulfide bonds (E form) [44]. The B form of HSA is suggested to have a
loss of rigidity in the amino-terminal region and the A form of HSA can be thought of as
an extension of the B form and is believed to have structural alterations primarily in
domains I and II [44].

One of the interesting structural features of HSA is that it contains only one tryptophan
residue (at position 214 in loop 4) and 35 cysteine residues, of which all but one
participate in disulfide bonds that act to stabilize the protein tertiary structure.
Cysteine34 does not participate in a disulfide bond and is located in a partially solvent
protected random coil region of the polypeptide chain between helices 2 and 3 in
domain I [49].

It is well known that the primary function of HSA is to bind and transport fatty acids.
However, the number and location of fatty acid binding sites is not as well known or
understood. Curry et al. [47] were the first to report the crystal structure of HSA
complexed with five myristate (C14:0) molecules. The locations of five myristate
binding sites were found to be long, hydrophobic pockets asymmetrically distributed
throughout the HSA molecule [47]. Upon fatty acid binding, domains I and III rotate
relative to domain II [48, 49]. More recently, Bhattacharya et al. [50] have identified
eleven distinct binding sites for medium- and long-chain fatty acids. There is a single
myristate binding site in sub-domain IB, one at the interface between IA and IIA, two
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sites in IIIA and one binding site in IIIB, all which had been identified previously [47].
Another site was suggested for myristate at the interface between IIA and IIB [50].
These six sites were also shown to bind capric, lauric, palmitic and stearic acids [50]. A
seventh site has been identified in a hydrophobic cavity of IIA that might be the primary
binding site for shorter-chain fatty acids [50]. Two additional binding sites for capric acid
(but not longer fatty acids) have also been discovered in a large crevice between
domains I and III [50]. Bhattacharya et al. [50] have also suggested that there are two
primary binding sites for long-chain fatty acids in domain I and domain III, however the
precise locations have yet to be identified.

1.4.3 Fluorescent Probes that Bind to HSA
In 1990, David Wilton [51] determined that 11-(dansylamino)undecanoic acid (DAUDA)
binds at the bilirubin binding sites of both BSA and HSA. The basis for this work was
earlier research that found that when DAUDA was bound to rat liver fatty-acid binding
protein there was a fluorescent emission enhancement accompanied by a blue-shift in
the emission maximum [52]. Similar emission enhancement and blue-shift of the
emission maximum was observed when DAUDA was in solution with either BSA or HSA
that was not observed for DAUDA in buffer [51]. Wilton used displacement studies to
determine the location of the DAUDA binding sites. He added DAUDA to an HSA
solution in a 1:1 molar ratio and then added stoichiometric amounts of oleic acid,
bilirubin, or octanoic acid and measured the change in fluorescence emission. Oleic
acid displaced the DAUDA (indicated by a loss of fluorescence) but only after 3 moles of
oleic acid had been added per mole of HSA, indicating that oleic acid was binding at the
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3 long-chain fatty acid sites first [51]. Octanoic acid (a medium-chain fatty acid) and
bilirubin both displaced DAUDA immediately; however, octanoic acid binds with a lower
affinity than bilirubin [51]. These results agree with earlier studies that proposed that
the high-affinity sites for fatty acids are separate from the bilirubin binding sites [53].
Wilton also used Scatchard analysis to determine that DAUDA binds to HSA at three
apparent sites, one high affinity and two lower-affinity sites [51]. Upon analysis, the
binding constants were found to be Kd less than 10-7M for the high affinity site and Kd of
approximately 8 × 10-7M for the two lower affinity sites [51]. These values are
comparable to bilirubin binding to HSA as reported by Jacobsen; Kd of about 10-8M for
one high affinity site and Kd of about 10-6M for two lower affinity sites [54].

5-(Dimethylamino)naphthalene-1-sulfonic acid (DNS) is the parent fluorophore of
DAUDA. Doody et al. have studied this fluorophore and it’s ability to bind to the
medium-chain fatty acid binding sites on HSA and BSA [55]. Using Scatchard analysis
they found that DNS bound to one major binding site (Kd = 2 × 10-7M) and one minor
binding site (Kd = 3 × 10-6M). Like DAUDA, DNS is displaced from the high affinity site
by medium-chain fatty acids [55]. The fluorescence emission maximum of DNS shifts
from 503 nm to 433 nm when DNS is bound to HSA and 436 nm when bound to BSA
(excitation 325 nm) [55]. Upon addition of dodecanoic acid, the emission spectra lost
fluorescence at the shorter wavelength and regained fluorescence at 503 nm, indicating
that the dodecanoic acid was displacing DNS from the medium-chain fatty acid binding
sites on albumin [55].
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1.4.4 Copper Binding to HSA
Copper(II) binding to HSA is unique because it binds more tightly and more specifically
to mammalian albumins than most other cations [44]. Copper binding to HSA was
originally found by accident in 1959 by Peters [44] while studying methods of albumin
cleavage. He found that the amino-terminal residue of BSA became undectable upon
dialysis against water. It soon became clear that the water used in the experiments had
a very low concentration of copper (10-8M) and that the BSA was scavenging the metal
ion from the water [44]. Copper(II) has since been shown to have a square planar
coordination to the first three amino acids of HSA, the N-terminal amine, the first two
deprotonated amides, and the His imidazole of the third residue [56]. The binding
affinity for copper(II) to HSA is so high that it is difficult to measure. Reported values for
KA range from 1.6 % 1011 to 1.6 % 1016 M-1 [44, 57, 58].

Albumin has been shown to act as an antioxidant that is capable of scavenging free
radicals thereby preventing lipid peroxidation [59]. Dobrian et al. [59] investigated the
antioxidant role that HSA played in the presence of LDL under oxidative conditions.
They found that peroxidation of LDL did not occur when it was incubated with albumin
[59]. Similar results indicating the antioxidant ability of albumin have been noted by
Thomas [60], Dasgupta and Zdunek [61], and Gutteridge and Wilkins [62]. Zawadzki et
al. [63] showed that the antioxidant ability of HSA was primarily because of the ability of
HSA to tightly bind copper ions.
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Chapter 2: Objectives
2.1 Project Background
By-products of lipid peroxidation, including E-2-hexenal, E-2-octenal, 4HNE, and 4ONE,
have been shown to modify nucleophilic amino acid residues, including lysine residues,
in proteins [1-7]. The produced α,β-unsaturated aldehydes are stable enough to
migrate from their site of origin, therefore coming into contact with a wide range of
biomolecules in the system. Human serum albumin (HSA) is the most abundant plasma
protein. It contains 58 lysine residues (approximately 10% of HSA), which are
distributed throughout the sequence and tertiary structure of the protein, several of
which are exposed to the surface (Figure 2.1), making them available to react with other
molecules in the system. Based on what is known about the ability of lipid peroxidation
by-products to react with lysine residues and the abundance of lysine residues in HSA,
we hypothesized that HSA could provide an outlet of consumption for the by-products
thereby eliminating the harmful lipid peroxidation by-products from the system. If HSA
serves as a potential “sink” of sorts for the reactive aldehydes, the effects that the byproducts have on the function of HSA must be addressed. The main objective of this
research was to examine the functional and structural modifications of HSA that occur in
the presence of lipid peroxidation by-products.
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Figure 2.1: Surface Lys residues in HSA. The image was created using
the crystal structure of HSA (1ao6) deposited in the Protein Data Bank
by Sugio et al. [8].

This laboratory has demonstrated that water-soluble fluorescence is observed in serum
samples collected from elderly subjects [9]. Elamin used gel filtration chromatography
to show that the water-soluble fluorescence from serum eluted in the fraction containing
primarily HSA (although other fluorescent proteins were subsequently identified) [9].
The purpose of the research described here was to more carefully characterize the
water-soluble fluorescence properties observed in serum samples collected from human
subjects. Based on the abundance of lysine residues in HSA and the ability of lipid
peroxidation by-products to travel through the system, it was proposed that a
modification of HSA by lipid peroxidation by-products is a major contributor to the
observed water-soluble fluorescence. The particular lipid peroxidation by-products used
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in this work were the α,β-unsaturated aldehydes, E-2-hexenal, E-2-octenal, 4HNE, and
4-ONE. The water-soluble fluorescence properties of HSA modified with the α,βunsaturated aldehydes mentioned above were characterized through a series of in vitro
experiments.

2.2 Specific Aims
The work described herein was based on the hypothesis that HSA can react with lipid
peroxidation derived α,β-unsaturated aldehydes to yield a fluorescently modified
protein. This hypothesis was investigated by studying the structural modifications of
HSA by lipid peroxidation by-products, the functional modifications of HSA by lipid
peroxidation by-products, and how lipid peroxidation by-products affect the ability of
HSA to act as an antioxidant.

The effects of reactive aldehydes on the structure and function of HSA were
investigated through the following specific aims:

•

Characterize the susceptibility of HSA to react with α,β-unsaturated aldehydes by
measuring comparable time courses of fluorescence development.

•

Ascertain the impact of modified HSA to bind fatty acids or surrogate molecules.

•

Determine relative sites of modification on HSA.
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•

Determine whether modification could compromise copper binding to HSA,
thereby diminishing antioxidant capacity by allowing an increase in the
concentration of free copper.

It was my hope that accomplishing the goals stated above would lead to important new
knowledge in the quest to better define the biochemical effects of lipid peroxidation byproducts on protein structure and function.
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Chapter 3: Materials and Methods

3.1 Materials
3.1.1 Reagents
Human serum albumin (A-3782) was from Sigma-Aldrich (St. Louis, MO) and was
approximately 99%, essentially fatty acid free and essentially globulin free. This grade
of human serum albumin was used for all experiments unless otherwise stated. Lower
grades of HSA were also used from Sigma (A-9511, A-1653, A-8763, and A-1887) in
experiments where the dependence of HSA purity on binding was investigated. A 6.6
mM sodium phosphate buffer containing 146 mM sodium chloride, 0.1 mM
ethylenediaminetetraacetic acid (EDTA) and a pH of 7.4 was used in all experiments,
unless otherwise noted.

4-Hydroxy-2-nonenal was supplied by CalBiochem (San Diego, CA, USA) and 4-oxo-2nonenal was synthesized in this laboratory by Seybert using the method of Chandra et
al. and Gardner et al. [1, 2]. E-2-hexenal (13,265-9) and E-2-octenal (26,995-6) were
from Aldrich (Milwaukee, WI, USA). 11-(dansylamino)undecanoic acid (D-94) was from
Molecular Probes (Eugene, OR, USA) and 5-(dimethylamino)naphthalene-1-sulfonic
acid hydrate (19,434-4) was supplied by Aldrich Chemical Company (Milwaukee, WI,
USA).

Iodoacetic acid, ammonia persulfate, acrylamide/bis-acrylamide, dithiothreitol, TEMED
and SDS-PAGE molecular weight standards (low range 6,500-66,000 and standard
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range 30,000-200,000) came from Sigma. 2-mercaptoethanol and Coomassie brilliant
blue were supplied by Bio-Rad (Hercules, CA, USA). Formic acid was purchased as an
88% certified ACS grade solution from Fisher Scientific (Pittsburgh, PA, USA). All
HPLC solvents were HPLC grade from Fisher and were filtered through a 0.2 µm nylon
membrane before use. All reagents used in SDS-PAGE gel preparation were
electrophoresis grade. Cyanogen bromide (CNBr) was purchased from Alfa Aesar
(Ward Hill, MA, USA).

3.1.2 Instrumentation
All fluorescence measurements were recorded on a Photon Technology International
(PTI) instrument. The fluorimeter was equipped with a MD-5020 motor driver, LPS-220
lamp power supply and a 814 photomultiplier detection system. FeliX for windows
(version 1.11) was used as the interface for the system. Fluorescence measurements
were normalized against a 1 × 10-4 mg/mL quinine solution prepared in 0.05 mM H2SO4.
Absorbance measurements were taken using either a Varian CARY-1 or a Varian
CARY-3E UV-Visible spectrophotometer with the accompanying CARY software.

Cyanogen bromide digested HSA fragments were separated by HPLC using a Waters
600 pump and 600 controller equipped with a Waters 2487 dual wavelength absorbance
detector and a Waters 470 scanning fluorescence detector. Data were collected and
analyzed using the Millenium software package, version 3.20. A Microsorb-MV C-18
column (25 cm % 4.6 mm I.D., 5 µm, 300 Å pore size) was used in all separations.
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Isothermal titration calorimetry (ITC) experiments were conducted using a Microcal
isothermal titration calorimetric unit with an Isotemp 3016 external water-bath and a
ThermoVac sample degassing and thermostat unit. Data were collected and analyzed
using the program Origin, version 5.0.

All mass spectrometry data were collected in collaboration with Dr. Mark Bier at the
Center for Molecular Analysis at Carnegie Mellon University in Pittsburgh,
Pennsylvania. Matrix assisted laser desorption ionization (MALDI) time of flight (TOF)
mass spectrometry was performed using a PerSeptive Biosystems Voyager STR
MALDI-TOF mass spectrometer funded by NSF grant number CHE-9808188.

3.2 Methods
3.2.1 SDS-PAGE Gels
Sodium dodecylsulfate polyacrylamide gel electrophoresis gels were prepared
according to the method of Laemmli [3]. All gels were run with 4% stacking gels and
either 10% or 20% separating gels. Protein was visualized on the gels by staining with
Coomassie blue. Gel images were obtained and subsequent analysis was performed
using a Kodak 1D imaging system and software package.

3.2.2 Cyanogen Bromide Treatment of HSA
10mg HSA was added to 1mL reduction medium (1M Tris-HCl pH 8.0, 6 M guanidineHCl, 0.05 M dithiothreitol) and was incubated under nitrogen for 3 hours at room
temperature. A 1.3 fold molar excess of iodoacetic acid over the concentration of total
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thiols was dissolved in 1mL water and was added to the HSA in reduction medium.
This was incubated in the dark at room temperature for 1 hour. 15 µL (0.2 mmol) 2mercaptoethanol was added to stop the reaction and the reduced and
carboxymethylated protein was dialyzed against water for 24 hours. After dialysis, the
HSA was flash frozen with dry ice / acetone and the sample was lyophilized. The
protein was redissolved in 2 mL of 70% formic acid containing a 100 fold molar excess
of CNBr over the methionine residues. HSA was incubated with CNBr under nitrogen in
the dark for 24 hours. The CNBr treated protein was diluted 20 fold with water and the
solvent was removed using the vacuum pump. The protein was then dissolved in 2 mL
0.1% TFA for a maximum protein concentration of 73 µM and was filtered through a 0.2
µm filter so that it was ready for HPLC analysis. HSA (50 mg/mL) was incubated with
30 mM E-2-hexenal, 0.07 mM E-2-hexenal, 1 mM 4HNE, 6.4 mM 4HNE, or 0.07 mM
4ONE for varying lengths of time at 37°C before reduction, carboxymethylation, and
cyanogen bromide treatment.

3.2.3 HPLC of Cyanogen Bromide Treated HSA
Cyanogen bromide treated HSA samples were separated using a modification of the
method of Campagnini and Iadarola [4, 5]. A 100 µL sample of fragmented protein
(approximately 7 nmole) was injected into a Microsorb-MV C-18 column (25 cm × 4.6
mm I.D., 5 µm, 300 Å pore size). The column was equilibrated with 80% solvent A
(0.05% aqueous TFA) and 20% solvent B (acetonitrile:2-propanol (2:1 v/v) with 0.08%
TFA). Elution was preformed at room temperature with a flow rate of 0.5 mL/min using
a 30-minute linear gradient beginning at 80% A and 20% B and ending at 40% A and
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60% B. The mobile phase was held at 40% A and 60% B for 15 minutes before it was
equilibrated back to 80% A and 20% B.

3.2.4 Time Course of Intramolecular and Intermolecular Cross-Linking of HSA
0.7 mM HSA was incubated at 37°C with either 30 mM E-2-hexenal, 6.4 mM 4HNE or
6.4 mM 4ONE. Before the addition of the aldehyde, a 5 µL aliquot of HSA was diluted
with 100 µL of SDS sample buffer. Immediately following aldehyde addition to HSA,
another 5 µL aliquot was diluted with sample buffer (t=0). Aliquots were also taken at 2,
6, 10, and 24 hours of incubation. All aliquots and a set of molecular weight standards
(Sigma SDS-6H) were run on 4% stacking and 10% separating SDS gels. Images of
the gels were captured and analyzed using a Kodak 1D Gel Imaging System and
analysis software. Percent band composition was determined by recording the net
intensities for native HSA, the ~83 kDa band, and the high molecular weight bands of
the same area for each lane on the gel. Molecular weights of the bands in the
experimental lanes were estimated by comparing the migration distances to those in the
standard lane using the analysis software provided with the imaging system.

3.2.5 Fluorescence Measurements
All raw fluorescence data were measured using a Photon Technology International
(PTI) Spectrofluorimeter and were normalized against a quinine standard (0.3 µM
quinine in 0.05 M H2SO4). Control samples of HSA (without aldehyde) were run in
parallel to the aldehyde modified HSA samples. Control samples did not show any
significant changes in fluorescence emission during the course of the experiments.
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3.2.5.1 Protein Fluorescence
To monitor the development of protein fluorescence, 0.15 mM HSA was incubated with
aldehyde (15 mM E-2-hexenal, 6.4 mM 4HNE, or 1 mM 4ONE) at 37 °C. At varying
time intervals, aliquots of the incubated sample were diluted with buffer to a final
concentration of 3 µM HSA and 20 µM to 300 µM aldehyde. Fluorescence was
measured with an excitation of 350 nm and an emission of 422 nm (4ONE), 430 nm (E2-hexenal) or 460 nm (4HNE). Data were fitted to two first order exponentials using the
program Origin, version 6 (Microcal Software, Inc., Northampton, MA 01060).

3.2.5.2 DAUDA Fluorescence
Changes in DAUDA fluorescence were monitored by incubating 0.15 mM HSA with
aldehyde (15 mM E-2-hexenal or 15 mM 4ONE) at 37 °C. After measuring protein
fluorescence (see above), DAUDA (0.75 mM in methanol) was added to a 3 mL
fluorescence cuvette to a final concentration of 7.2 µM DAUDA. The solution was
allowed to reach equilibrium before measuring the fluorescence (excitation of 350 nm
and emission of 510 nm). Data were fitted using a second order exponential function in
the Origin program.

3.2.5.3 DNS Fluorescence
DNS fluorescence was measured by incubating 0.7 mM HSA with aldehyde (15 mM E2-hexenal, 6.4 mM 4HNE or 1 mM 4ONE) at 37 °C. At given time intervals, aliquots of
the incubated protein solution were diluted with buffer to a final concentration of 1 µM
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HSA. DNS (5 mM in ethanol) was added to a final concentration of 5 µM DNS. The
solution was allowed to reach equilibrium and fluorescence emission was recorded at
425 nm (excitation of 325 nm). At each time point aliquots were taken in triplicate.
Plots and standard deviations were generated using Origin, version 6.

3.2.5.4 DNS Titrations / Scatchard Plots
DNS was prepared as a 1 mM solution containing 50% ethanol at a pH of 7.4. 1 mM
HSA was incubated with 15 mM E-2-hexenal for 24 hours at 37 °C. The incubated
protein was titrated into a cuvette containing 4 µM, 5 µM, or 10 µM DNS. Fluorescence
spectra were obtained after the solution reached equilibrium. The fluorescence
emission was monitored at 425 nm (excitation 325 nm). The titrations were analyzed as
Scatchard plots and was fitted using Microsoft Excel 2000. The maximum fluorescence
was determined when the addition of HSA ceased to cause an increase in the
fluorescence emission intensity.

3.2.5.5 DNS Equilibrium Dialysis / Scatchard Plots
0.7 mM HSA was incubated with or without 30 mM E-2-hexenal or 30 mM 4ONE for 2
hours at 37°C. Varying concentrations (40 µM to 260 µM) of HSA were added to SlideA-Lyzer Dialysis Units (Pierce, Rockford, IL 61105) with a molecular weight cut-off of
10,000 Da. 100 µM DNS was also added to the dialysis units. The total volume in the
dialysis unit was adjusted to 200 µL with NaPi buffer. DNS was allowed to equilibrate
for 24 hours at 4 °C with 1 mL NaPi buffer in a 1.5 mL microcentrifuge tube. After
equilibration, the HSA in the dialysis unit was denatured (releasing all bound DNS) with
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2% SDS. DNS fluorescence was measured in a 3 mL cuvette (excitation 325 nm,
emission 503 nm). This fluorescence measurement represented the bound and free
DNS. Free DNS was measured by fluorescence using the 1 mL volume from the
microcentrifuge tube plus 1 mL NaPi buffer. Fluorescence from both sides of the
dialysis membrane was corrected for dilution and was converted to concentration of
DNS using a calibration curve. Subtraction of free DNS (from the microcentrifuge tube)
from bound plus free DNS (from the dialysis unit) gave a direct measurement of bound
DNS. This data was then analyzed as Scatchard plots to determine information about
the number of DNS binding sites on HSA and the binding affinity of DNS to these sites.

3.2.6 Matrix Assisted Laser Desorption Ionization (MALDI) Time Of Flight (TOF)
Mass Spectrometry (MS)
All MALDI-TOF MS was done in collaboration with Dr. Mark Bier at the Center for
Molecular Analysis at Carnegie Mellon University in Pittsburgh, Pennsylvania. CNBr
treated unmodified and 4ONE modified HSA fragments were separated on a reversed
phase HPLC column as described in section 3.2.3 of this chapter. Individual peaks of
several HPLC runs were collected based on retention time (Table 3.1). Pooled fraction
6 from several HPLC runs, which contained the fluorophore in the 4ONE modified HSA,
was concentrated under a stream of nitrogen gas and was re-filtered through a 0.2 µm
filter. The matrix used for MALDI-TOF MS was 10 mg sinapinic acid in 1 mL of 50%
acetonitrile / 50% water containing a small amount of acetic acid. The MALDI-TOF
sample was prepared by mixing 10 µL of the matrix with 10 µL of concentrated fraction
6 and was loaded onto a 100 well plate. After the solvent evaporated, the plate was
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loaded into the MS and data was collected. The MS was calibrated with apo-myoglobin
(MW = 17,000 Da).

Fraction Number
1
2
3
4
5
6

Fragment Number
2
4
7
6
3
1 and 5 + fluorescence
species

Retention Time (min)
19.5 – 21.5
28.5 – 30.3
30.3 – 31.3
31.3 – 33.0
33.0 – 35.0
35.0 – 39.0

Table 3.1: Table of fractions collected from CNBr treated HSA
separated on a reversed phase HPLC column, corresponding HSA
peptide fragment number, and retention times.

3.2.7 Isothermal Titration Calorimetry (ITC)
ITC was used to measure copper binding to HSA. The buffer used for all ITC
experiments was 0.1 M borate, 0.1 M Tris, 20 mM NaCl at a pH of 9.2. A 100 mM stock
solution of copper (II) sulfate was diluted to a 1.0 mM solution for injection into a
solution of 54 µM HSA in buffer. ITC parameters were modeled after those of Zhang et
al. [6]. The cell temperature was set to 25 °C with the circulating water bath set to 10
°C. Twenty-two injections of 8 µL per injection were made for each experiment. The
initial delay was 1440 seconds and there were 720 seconds between each injection.
The 101.8 µL/in syringe was used. Other parameters set were reference offset = 50%,
t1 = 2 s, t2 = 4 s, and tswitch = 210 s. Data was analyzed in Origin, version 5.0, and was
fit to a one-site model. Blank titrations of 1 mM copper (II) sulfate titrated into buffer
were done. The blank was subtracted from every experimental titration (1 mM copper
(II) sulfate titrated into 54 µM HSA). This was done to eliminate the heat of injection and
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heat of dilution from each experiment so that only the heat of copper binding was used
for subsequent calculations.

0.7 mM HSA was incubated at 37 °C for two hours with 15 mM or 1mM E-2-hexenal or
15 mM or 1 mM 4ONE in borate/tris buffer, pH 9.2. After incubation, the protein was
diluted to a concentration of 54 µM HSA. Titrations of modified HSA were blanked with
a titration of 1 mM copper (II) sulfate titrated into buffer containing the appropriate
aldehyde. Analysis for aldehyde modified HSA titrations was done exactly the same as
unmodified HSA titrations.
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Chapter 4: Results

4.1 Time Course of Protein Fluorescence
Several groups have noted that upon incubation with an α,β-unsaturated aldehyde,
proteins will develop fluorescence [1-4]. The observed fluorescence has the same
characteristics as those of lipofuscion and ceroid, namely an excitation maximum
between 340 and 390 nm and emission maximum of 400 to 600 nm [2, 3]. Lipofuscion
and ceroid are fluorescent materials that have been found to accumulate in postmitotic
cells with age [5] and have also been observed within intracellular granules of
postmitotic cells that are partially composed of damaged protein and lipid [3].

The time course for protein fluorescence was followed when HSA was incubated with E2-hexenal, 4HNE, or 4ONE. There was no change in the fluorescence for the HSA
sample incubated without aldehyde (control sample). The time course of protein
fluorescence was fit to two first order rate constants for E-2-hexenal modified HSA; k1 =
1.2 × 10-2 ± 2.8 ×10-3 min-1 and k2 = 3.7 × 10-4 ± 1.2 × 10-4 min-1 (Figure 4.1). The time
course of protein fluorescence for 4ONE modified HSA was also fit to two first order rate
constants; k1 = 3.9 × 10-2 ± 9.7 × 10-3 min-1 and k2 = 5.6 × 10-3 ± 3.6 × 10-3 min-1 (Figure
4.2). Protein fluorescence for 4ONE modified HSA developed at a faster rate than did
E-2-hexenal modified HSA. The extent of protein fluorescence enhancement for 4ONE
modified HSA was greater than that of E-2-hexenal modified HSA.

47

A

B

120

25

100

80

Normalized Fluorescence
(Ex. 350nm, Em. 430nm)

Normalized Fluorescence
(Ex. 350nm, Em. 430nm)

20

60

40

20

15

10

5

0
0
0

20

40

60

80

100

120

140

160

180

0.0

0.5

Time (hours)

1.0

1.5

2.0

Time (hours)

Figure 4.1: Time course of development of protein fluorescence for
0.15mM HSA incubated with 15mM E-2-hexenal. (A) Data were fit to two
exponentials and rate constants were determined; k1 = 1.5 × 10-2 min-1
and k2 = 3.2 × 10-4 min-1. (B) Expanded region of panel showing the
control («) and E-2-hexenal modified (») samples for the first 2 hours of
the experiment.
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Figure 4.2: Time course of development of protein fluorescence for
0.15mM HSA incubated with 1mM 4ONE. (A) Data were fit to two
exponentials and rate constants were determined; k1 = 3.4 × 10-2 min-1
and k2 = 3.1 × 10-3 min-1. (B) Expanded region of panel showing the
control («) and 4ONE modified (») samples for the first 0.75 hours of
the experiment.

Incubation of HSA with 4HNE resulted in an immediate but small (approximately 6
fluorescence units) increase in the protein fluorescence (Figure 4.3). There was no
further change in the protein fluorescence of the 4HNE modified sample in the
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subsequent 24 hours of incubation. The immediate increase in protein fluorescence
observed for 4HNE modified HSA (compared to control HSA) was greater than the
fluorescence difference observed between either control or E-2-hexenal and 4ONE
modified HSA (Figures 4.1B, 4.2B, and 4.3).
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Figure 4.3: Time course of protein fluorescence for 0.15mM HSA
incubated with 1mM 4HNE, control («) and 4HNE modified (»).

In a separate experiment, the time courses of fluorophore formation in HSA were
compared using equivalent concentrations of E-2-hexenal and 4HNE. The protein
fluorescence of 4HNE modified HSA showed an immediate enhancement of emission
that did not increase again until an additional aliquot of 4HNE was added (Figure 4.4).
In contrast, addition of equivalent concentrations of E-2-hexenal to an HSA solution
resulted in a time based increase in the protein fluorescence emission. This indicates
that there is a difference in the pathway of fluorophore formation between the two
aldehydes.
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Figure 4.4: Time course of protein fluorescence for Control HSA (■), E2-hexenal modified HSA ( ) and 4HNE modified HSA (▲). After 2 hours
of incubation at 37°C, an additional amount of aldehyde was added to
the incubation mixture and fluorescence was immediately measured.
Higher aldehyde concentration is indicated with an arrow.

Modification of HSA by different concentrations of E-2-hexneal was also investigated.
HSA was incubated with 1mM E-2-hexenal or 15mM E-2-hexenal. Protein fluorescence
was measured initially, at one hour of incubation at 37ºC and after 24 hours of
incubation at 37ºC (Figure 4.5). Initial rates of protein fluorescence development were
determined using the zero and one-hour time points. The initial rate for 15mM E-2hexenal is 14.5 times faster than for 1mM E-2-hexenal, indicating pseudo first order
conditions.
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Figure 4.5: Protein fluorescence dependence on E-2-hexenal
concentration. Time course of protein fluorescence for control HSA (■)
and HSA incubated with either 15mM E-2-hexenal ( ) or 1mM E-2hexenal (<).

4.2 DAUDA Binding
It has been reported that 11-(dansylamino)undecanoic acid (DAUDA) (Figure 4.6) binds
to three of the medium-chain fatty acid sites (bilirubin binding sites) on HSA [6].
Fluorescence is immediately lost when albumin-bound DAUDA is titrated with bilirubin,
indicating that DAUDA binds at the bilirubin binding sites [6]. Therefore, DAUDA proves
useful in investigating the possible modification of the medium-chain fatty acid binding
sites of HSA when incubated with an α,β-unsaturated aldehyde. DAUDA in a buffer
solution has relatively no fluorescence, however, a solution of albumin plus DAUDA has
an enhanced emission at 500nm [6].
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Figure 4.6: Structure of 11-(dansylamino)undecanoic acid (DAUDA).
Upon binding to the medium-chain fatty acid binding sites of HSA, the
fluorescent properties of DAUDA change.

In order to use DAUDA to monitor changes in the medium-chain fatty acid binding sites
of HSA, I made the assumption that a loss of fluorescence emission at 510nm reflected
a loss of DAUDA binding to HSA. Presumably, loss of binding was the result of
aldehyde-induced modifications preventing DAUDA from binding to HSA. DAUDA
fluorescence was lost upon incubation of HSA with E-2-hexenal (Figure 4.7). Rate
constants for the loss of enhanced DAUDA fluorescence were determined for E-2hexenal modified HSA; k1 = 1.6 × 10-2 ± 3.5 × 10-3 min-1 and k2 = 7.8 × 10-4 ± 8.8 × 10-4
min-1. Enhanced DAUDA fluorescence was also lost for 4ONE modified HSA (Figure
4.8); k1 = 4.5 × 10-2 ± 1.6 × 10-2 min-1 and k2 = 6.1 × 10-3 ± 3.2 × 10-3 min-1. HSA
samples incubated without aldehyde did not show a loss of DAUDA fluorescence over
the course of the experiment. Approximately 50% of the fluorescence (compared to the
unmodified HSA sample) was lost immediately upon the addition of 4ONE while only
about 13% of the initial fluorescence was lost for the E-2-hexenal modified sample.
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Figure 4.7: DAUDA fluorescence of E-2-hexenal modified HSA.
0.15mM HSA incubated with 15mM E-2-hexenal plus 7.2µM DAUDA.
Data was fit to two exponentials and rate constants for loss of DAUDA
binding were determined; k1 = 1.8 × 10-2 min-1 and k2 = 1.4 × 10-3 min-1.
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Figure 4.8: DAUDA fluorescence of 4ONE modified HSA. 0.15mM HSA
incubated with 15mM 4ONE plus 7.2µM DAUDA. Data was fit to two
exponentials and rate constants for loss of DAUDA binding were
determined; k1 = 5.6 × 10-2 min-1 and k2 = 8.3 × 10-3 min-1.
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Based on Scatchard analysis of fluorescence data, Wilton [6] proposed that DAUDA
bound to three sites (one high-affinity site and two lower-affinity sites having similar
affinities) on HSA. The amount of bound DAUDA was quantified by measuring the
fluorescence intensity of a known concentration of bound DAUDA and adding excess
albumin [6]. It was also necessary for Wilton to make the assumption that all DAUDA
binding sites on HSA showed similar fluorescent-enhancement properties in order to
construct Scatchard plots [6].

In order to use Wilton’s Scatchard analysis to gain information about the binding affinity
and number of binding sites for aldehyde-modified HSA, it was necessary to quantify
the amount of HSA to be added for fluorescence emission to reflect all DAUDA bound.
HSA was titrated into a fixed amount of DAUDA and fluorescence emission was
monitored (Figure 4.9). Fluorescence of DAUDA in buffer was subtracted from all
readings so that the plotted fluorescence only reflects DAUDA bound to HSA. Contrary
to what was expected, addition of excess HSA caused the fluorescence to decrease
with increasing HSA. The same trend was observed for DAUDA concentrations of
15µM, and 45µM (data not shown). This proved to be a problem when determining the
maximum fluorescence of bound DAUDA, therefore complicating the generation of
Scatchard plots from titration data.
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Figure 4.9: DAUDA enhanced fluorescence of HSA titrated into a
solution containing 2µM DAUDA.

In an attempt to try to eliminate this problem, the ionic strength of the phosphate buffer
used was varied. (Initial titrations of DAUDA and HSA were done using a 100mM
sodium phosphate buffer with 1mM EDTA at pH 7.4.) A 6.6mM sodium phosphate
buffer with 0.1mM EDTA and either 0mM, 146mM, 500mM, or 1M NaCl at pH 7.4 was
used and the titrations (15µM DAUDA with additions of HSA) were repeated (Figure
4.10). The emission spectra for each titration were significantly different from each
other (Figure 4.11) in that the more predominant emission peak was around 450nm and
the fluorescence enhancement for each buffer was different.
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Figure 4.10: Effect of ionic strength on DAUDA enhanced fluorescence.
HSA was titrated into a 15µM DAUDA solution in a sodium phosphate
buffer containing 0mM (■), 146mM ( ), 500mM (+), or 1M (∆) NaCl.
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Figure 4.11: Fluorescence spectra of 15µM DAUDA and 0.5mM HSA in
a 6.6mM sorium phosphate buffer with either 0mM NaCl (---), 146mM
NaCl (---), 500mM NaCl (---) or 1M NaCl (---) and 0.1mM EDTA at pH
7.4.
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Titrations of varying sources of HSA into a fixed amount of DAUDA were performed in
order to see if the preparation of HSA had an effect on the titration curve. Four HSA
grades from Sigma (A1653, A9511, A8763, and A3782) and a 50mg/mL HSA solution
from Irvine Scientific were titrated into a cuvette containing 15µM DAUDA. Sigma
A1653 is a Fraction V powder that is 96 to 99% albumin. Sigma A9511 is 97 to 99%
albumin and has been crystallized once and lyophilized. Sigma A8763 is essentially a
globulin free lyophilized powder that has been determined by agarose electrophoresis to
be 99% and is prepared from human albumin Sigma A1653. Sigma A3782 is the purest
form of human albumin sold by Sigma. It is approximately 99% and is essentially fatty
acid free. Before use in this titration, A3782 was further purified from high and low
molecular weight contaminants by passing it through a Sephadex G-75 column. A
6.6mM sodium phosphate buffer with 146mM NaCl and 0.1mM EDTA at pH 7.4 was
used for all titrations. Different preparations of HSA gave different fluorescence
emission spectra (Figure 4.12).
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Figure 4.12: Fluorescence spectra of 15mM DAUDA and 0.3mM HSA
of different preparations; Irvine Scientific (---), G-75 column purified (---),
Sigma A1653 (---), Sigma A9511 (---), and Sigma A8763 (---).

Could the variations seen in the emission spectra reflect DAUDA binding to different
sites based on the amount and type of fatty acid bound to the commercial HSA? It was
important to investigate this because if DAUDA binding to different sites gave different
fluorescence properties, then Wilton would not have been correct to assume that all
binding sites for DAUDA showed similar fluorescent properties when generating his
Scatchard plots [6]. When titrated into a solution of fatty-acid free HSA, the DAUDA
emission spectra showed an additional peak at a shorter wavelength that increases in
intensity as the concentration of HSA increases and the 500nm peak decreases. All
other purities of HSA titrated with DAUDA also showed the shorter wavelength peak,
however its intensity did not change in comparison to the emission peak at 500nm.
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Fatty-acid free HSA was titrated with fatty acids of varying length to determine if either
of the DAUDA fluorescence peaks could be identified as the long- or medium-chain fatty
acid binding sites. There were no significant differences in DAUDA displacement for
either wavelength based on the fatty acid used in the titration (Figure 4.13).
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Figure 4.13: Comparison of fatty acid chain length with DAUDA
displacement. Fluorescence emission is recorded at 500nm and is
normalized against a quinine standard. Oleic Acid (■), Decanoic Acid
(○), Octanoic Acid (▲), Heptanoic Acid ( ), and Bilirubin (∆).

Because the two emission peaks are so closely overlapped, it might be possible that the
relationship between long- or medium-chain fatty acid binding sites and the
fluorescence peaks is hidden. The Solver component in Excel was used to try and
deconvolute the overlapped fluorescence peaks to determine if there was a relationship
between DAUDA binding and either of the fluorescence emission peaks. Each
spectrum was separated into peaks, however the peak maximum for each of the
separated peaks was not consistent for each of the peaks in the titration. Solver
separated the overlapped peaks into two peaks with emission maximums in a 50nm
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range of each other. This lead to the inability of Solver to separate the fluorescence
spectra into peaks at consistent wavelengths from experiment to experiment.
Therefore, any relationship between fluorescence emission and fatty acid binding sites
could not be determined using this method. Origin was also used to deconvolute the
overlapped peaks into individual peaks. Again, the problem that we encountered was
that each spectrum in the titration separated into peaks within a 20nm range. It was
possible to limit the wavelengths that the component peaks should be at, however,
when this was done, the fits were not as good as when the wavelength was not fixed.
Another difficulty was that Solver and Origin gave different emission maxima for the
component peaks. For example, Solver deconvoluted a spectrum of 2µL DAUDA in
HSA into two peaks, one centered at 465nm and the other at 509nm. When the same
spectrum was deconvoluted with Origin, the component peaks were centered at 472nm
and 519nm. Because of the variance in the emission maximum of the component
peaks, there was no way to accurately determine the location of the component peaks.

Despite the difficulties described above with DAUDA binding to HSA, we were still
interested in determining information regarding binding site modification upon incubation
with an α,β-unsaturated aldehyde. DAUDA was titrated into a fluorescence cuvette
containing a known concentration of HSA. DAUDA was added until the fluorescence
reached a plateau. Taking the ratio of observed fluorescence to maximum fluorescence
and multiplying by the number of DAUDA binding sites on HSA and the total HSA
concentration gave the concentration of bound DAUDA. The free DAUDA concentration
was calculated from the difference of the total DAUDA minus the calculated bound
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DAUDA. Plots of three times the ratio of observed fluorescence to maximum
fluorescence versus the free DAUDA concentration were fit to an exponential process
and rate constants could be determined. This method made the assumption that there
were three DAUDA binding sites on HSA. Double reciprocal plots of corrected
normalized fluorescence-1 vs. [DNS]-1 were also generated from the titration data. The
double reciprocal plots were not linear (data not shown). Unmodified HSA was
incubated at 37°C for 24 hours. At time points, an aliquot of HSA was titrated with
DAUDA. No differences were observed in the titration curves for aliquots removed
during the 24-hour incubation period (Figure 4.14). E-2-hexenal modified HSA lost
approximately 30% of DAUDA binding fluorescence during the first three hours of
incubation at 37°C (Figure 4.15). An additional minimal amount of DAUDA binding
fluorescence is lost between 3 and 24 hours for a total loss of DAUDA binding
fluorescence of 40%.
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Figure 4.14: 0.15mM HSA incubated at 37°C. At 0 hours (♦), 1 hour
( ), 3 hours (∆), and 24 hours (×), an aliquot was pulled and titrated with
DAUDA. Fluorescence was measured with an excitation of 350nm and
emission of 510nm and was normalized against quinine.
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Figure 4.15: 0.15mM HSA incubated with 15mM E-2-hexenal at 37°C.
At 0 hours (♦), 1 hour ( ), 3 hours (∆), and 24 hours (×), an aliquot was
pulled and titrated with DAUDA. Fluorescence was measured with an
excitation of 350nm and emission of 510nm and was normalized against
quinine.

4.3 DNS Binding
Due to the unexpected complications involved with measuring changes in DAUDA
binding to HSA upon modification with α,β-unsaturated aldehydes, we decided to use a
fluorescent probe closely related to DAUDA, 5-(dimethylamino)napthtalene-1-sulfonic
acid (DNS) (Figure 4.16), to investigate the medium-chain fatty acid binding sites on
HSA. DNS has been described as the parent fluorophore of DAUDA with the only
difference between the two structures being the absence of DAUDA’s long carbon chain
on DNS. DNS has been shown to bind reversibly to the medium-chain fatty acid
(bilirubin) binding sites on HSA [7]. DNS purportedly binds to two sites on HSA as
determined by Scatchard analysis with one high-affinity site having a Kd of ~2 × 10-7 M
and a low-affinity site with a Kd of ~3 × 10-6 M [7]. DNS has similar fluorescent
characteristics to DAUDA, but binds to HSA with slightly lower affinity [6, 7]. Upon
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binding to HSA, the maximum fluorescence emission (excitation at 325nm) of DNS
shifts from 503 nm to 433 nm and there is an increase in the fluorescence quantum
yield [7]. The enhancement of fluorescence emission at 433 nm is diminished when
dodecanoic acid is added to a solution of DNS and HSA, indicating competitive binding
between DNS and dodecanoic acid (Figure 4.17) [7]. Doody et al. [7] suggest that the
isoemittive point (at approximately 500nm) in the fluorescence spectra indicate that
DNS bound to the low-affinity site has similar fluorescence behavior as DNS bound to
the high-affinity site.
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Figure 4.16: Structure of 5-(dimethylamino)naphthalene-1-sulfonic acid
(DNS). The fluorescent properties of DNS change upon binding to the
medium-chain fatty acid binding sites of HSA.
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Figure 4.17: Fluorescence spectra of 1µM DNS (red), 1µM DNS and
1µM HSA (orange), 1µM DNS, 1µM HSA, and 1µM dodecanoic acid
(green), 1µM DNS, 1µM HSA, and 2µM dodecanoic acid (blue).
Excitation was set at 325 nm.

Titrations of fatty acid free HSA into a fixed concentration of DNS were done in order to
obtain information regarding the number and affinity for DNS binding sites on HSA. E2-hexenal modified HSA or unmodified HSA was titrated into 4µM (Figure 4.18), 5µM
(Figure 4.19), or 10µM (Figure 4.20) DNS until maximum fluorescence emission was
obtained. In all three titrations, E-2-hexenal modified HSA yielded less fluorescence
than the unmodified HSA. Presumably, less fluorescence indicated fewer DNS
molecules bound to HSA. These titrations suggest that the modification induced by E-2hexenal results in the loss of DNS binding site(s).
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Figure 4.18: 4µM DNS titrated with unmodified HSA (■) or 15mM E-2hexenal modified HSA («). Fluorescence was normalized against
quinine and corrected by subtracting out the fluorescence emission of
4µM DNS.
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Figure 4.19: 5µM DNS titrated with unmodified HSA (■) or 15mM E-2hexenal modified HSA («). Fluorescence was normalized against
quinine and corrected by subtracting out the fluorescence emission of
5µM DNS.
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Figure 4.20: 10µM DNS titrated with unmodified HSA (■) or 15mM E-2hexenal modified HSA («). Fluorescence was normalized against
quinine and corrected by subtracting out the fluorescence emission of
10µM DNS.

The tiration data were compiled and analyzed as Scatchard plots for unmodified HSA
(Figure 4.21) and 15mM E-2-hexenal modified HSA (Figure 4.22). Doody et al. [7] used
the same method to generate Scatchard plots and binding information for DNS binding
to HSA. Doody calculated that there was one major binding site (Kd1 = 2 × 10-7M and n1
= 0.75) and one minor binding site (Kd2 = 3.3 × 10-6M and n2 = 2.0) [7]. Scatchard plots
of unmodified HSA indicate that HSA has two DNS binding sites, one high affinity site
(Kd1 = (2.6 ± 1.2) × 10-7 M) and one low affinity site (Kd2 = (1.7 ± 0.9) × 10-6 M). The
Scatchard plots for 15mM E-2-hexenal modified HSA do not indicate a loss of DNS
binding sites, but rather an increased affinity for DNS binding at both sites, Kd1 = (3.5 ±
3) × 10-8 M, and Kd2 = (4.5 ± 1.5) × 10-7 M.
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Figure 4.21: Scatchard plot of unmodified HSA incubated for 24 hours
at 37°C generated from HSA titrated into 4mM (∆), 5mM (▲), or 10mM
( ) DNS. Kd1 = 3.3 × 10-7M, n1 = 0.84, Kd2 = 1.1 × 10-6M, n2 = 1.4.
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Figure 4.22: Scatchard plot of 15mM E-2-hexenal modified HSA
incubated for 24 hours at 37°C generated from HSA titrated into 4mM
(∆), 5mM (▲), or 10mM ( ) DNS. Kd1 = 7.2 × 10-8M, n1 = 0.8, Kd2 = 5.4 ×
10-7M, n2 = 1.3.

It was very puzzling that Scatchard analysis of E-2-hexenal modified HSA did not show
a loss of a DNS binding site even though the titrations yielded a lower amount of
fluorescence for the aledhyde modified HSA. In an attempt to gather more information
about the number of DNS binding sites on HSA, additional titrations were done at a
higher HSA concentration so that all of the DNS added would bind to all of the DNS
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binding sites on the HSA. After all of the DNS binding sites are occupied by DNS,
additional amounts of DNS will not bind to HSA and therefore, the DNS binding
fluorescence will not change. 10µM HSA was titrated with 1mM DNS and the data was
plotted as a ratio of the [DNS] to [HSA] versus normalized fluorescence. The data was
fit to straight lines and the x-axis value corresponding to the point where the lines
intersected was taken as the number of DNS binding sites per HSA molecule. Using
differences in the change of slope as a guide, the unmodified HSA was fit to two DNS
binding sites having different affinities (Figure 4.23). E-2-hexenal modified HSA was
also titrated with DNS (Figure 4.24). Because of the small change in fluorescence
emission, it was not possible to fit the data to determine the number of DNS binding
sites on E-2-hexenal modified HSA. Unmodified HSA resulted in a higher fluorescence
emission than did 15mM E-2-hexenal modified HSA.
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Figure 4.23: 10µM HSA titrated with 1mM DNS. Fluorescence was
measured with an excitation wavelength of 325nm, emission wavelength
of 425nm and was normalized with quinine. Data was fit to straight lines
that intersected at [DNS]:[HSA] values of 0.9 and 2.0.
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Figure 4.24: 10µM HSA modified by 15mM E-2-hexenal titrated with
1mM DNS. Fluorescence was measured with an excitation wavelength
of 325nm, emission wavelength of 425nm and was normalized with
quinine.

DNS binding fluorescence was lost with time upon incubation of HSA with E-2-hexenal
(Figure 4.25), 4ONE (Figure 4.26) and 4HNE (Figure 4.27). Time courses of protein
fluorescence and DAUDA binding fluorescence mirror the time courses of DNS binding
fluorescence in that there appears to be a gradual loss of DNS binding fluorescence for
the E-2-hexenal and 4ONE modified HSA samples. This loss occurs during the first 2
hours of incubation at 37°C and then additional DNS binding fluorescence does not
appear to be lost. A rate constant of 1.3 % 10-2 min-1 was estimated for the loss of DNS
binding to E-2-hexenal modified HSA. Loss of DNS binding fluorescence in 4ONE
modified HSA occurred at a faster rate than the E-2-hexenal modified sample but could
not be quantified from these experiments. In contrast, DNS binding fluorescence is lost
immediately with the 4HNE sample and no additional loss of fluorescence is observed.
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Figure 4.25: 0.7mM HSA was incubated with 15mM E-2-hexenal ( )
and as a control (■). At a time point, the HSA was diluted to 9 × 10-4 mM
and 5 × 10-3 mM DNS was added. DNS binding fluorescence was
measured (Ex. 325nm, and Em. 425nm) and was normalized against
quinine. All time points were taken in triplicate.
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Figure 4.26: 0.7mM HSA was incubated with 1mM 4ONE ( ) and as a
control (■). At a time point, the HSA was diluted to 9 × 10-4 mM and 5 ×
10-3 mM DNS was added. DNS binding fluorescence was measured (Ex.
325nm, and Em. 425nm) and was normalized against quinine. All time
points were taken in triplicate.
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Figure 4.27: 0.7mM HSA was incubated with 6.4mM 4ONE ( ) and as a
control (■). At a time point, the HSA was diluted to 9 × 10-4 mM and 5 ×
10-3 mM DNS was added. DNS binding fluorescence was measured (Ex.
325nm, and Em. 425nm) and was normalized against quinine. All time
points were taken in triplicate.

The conflicting results between the titration data and Scatchard plots generated from
the titrations were puzzling. In an attempt to clarify some of the questions, equilibrium
dialysis experiments were designed to provide a direct measure of free and bound DNS.
Data from the equilibrium dialysis experiments could also be analyzed via Scatchard
analysis that would either support the earlier Scatchard results or would give additional
information about what was happening to the DNS binding sites on HSA. Microdialysis
cartridges from Pierce Biotechnology were used for these experiments. A fixed amount
of DNS was added to the upper chamber of each cartridge with increasing amounts of
HSA. Buffer was added to each of the bottom chambers and the system was allowed to
equilibrate. The theory behind the experiment was that DNS would bind to the HSA and
the unbound DNS would equilibrate across the membrane. It would then be possible to
measure the unbound DNS from the bottom chamber of each cartridge. The HSA in the
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upper chamber was denatured with SDS, causing the HSA to release the bound DNS.
Total DNS could then be measured from the upper chamber and after subtraction of the
free DNS from the bottom chamber, the amount of bound DNS was calculated.
Fluorescence was measured for samples of HSA, DNS, and SDS to ensure that
addition of SDS did not cause a loss of DNS fluorescence and that all of the DNS would
be released from the HSA upon denaturation (Figure 4.28). Five samples were
prepared: HSA + SDS + DNS, HSA + DNS, SDS + DNS, buffer + DNS, and buffer +
SDS. Fluorescence of HSA + DNS showed an enhanced and blue-shifted emission of
the fluorescence spectra. The sample containing buffer and SDS did not have any
fluorescence emission. Samples containing HSA with DNS denatured by SDS and
buffer with DNS exhibited identical fluorescence emission spectra indicating that all of
the DNS is released from HSA when it is denatured with SDS and that SDS does not
interfere with the emission properties of DNS. Although preliminary Scatchard plots
were generated using this method, the results were not reproducible (Figure 4.29). The
amount of DNS added to each of the dialysis cartridges (100µM) could not be
accounted for at the end of equilibration. Between 40µM DNS and 60µM DNS was
measured via fluorescence at the end of dialysis. This suggested that DNS was binding
to the dialysis membrane. Because of the apparent binding of DNS to the dialysis
membrane, it was not possible to obtain reliable measurements of free and bound DNS
for each cartridge.
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Figure 4.28: Fluorescence emission spectra of HSA + DNS (black),
HSA + DNS denatured with SDS (yellow), DNS in buffer (green), DNS in
buffer + SDS (blue), and SDS in buffer (red). Excitation was set at
325nm, and emission was measured from 360nm to 600 nm.
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Figure 4.29: Scatchard plots generated from equilibrium dialysis
experiments of unmodified HSA. Plots shown in (A) and (B) were done
as separate but identical experiments and show that the results obtained
were not reproducible.

4.4 Quantitation of Cysteine Residue
HSA has one cysteine residue (Cys34) that does not participate in disulfide bonds.
Because DAUDA and DNS binding fluorescence were lost more rapidly than protein
fluorescence developed, the possibility was considered that Cys34 modification by the
α,β-unsaturated aldehyde resulted in the loss of a DAUDA or DNS binding
fluorescence, but not the development of protein fluorescence. 5,5’-dithiolbis[2nitrobenzoic acid] (Ellman’s reagent) was used to detect the Cys34 in unmodified HSA
and E-2-hexenal modified HSA. Reaction of Ellman’s reagent with unmodified HSA
proceeded with a rate of 0.10 min-1 yielding the detection of 0.3 thiol groups per albumin
(Figure 4.30). Reaction of Ellman’s reagent with 15mM E-2-hexenal modified HSA with
a rate of 0.0004min-1 and yielded 0.4 thiols per HSA (Figure 4.31). It does not appear
that the thiol from Cys34 is modified by incubation with E-2-hexenal.
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Figure 4.30: 0.25mM unmodified HSA incubated for 15 hours at 37ºC
followed by reaction with Ellman’s reagent to detect free Cys residues.
The rate of detection of thiol groups was 0.10min-1.

0.5

[SH] / [HSA]

0.4

0.3

0.2

0.1

0.0
0

500

1000

1500

2000

2500

3000

Time (minutes)

Figure 4.31: 0.25mM HSA incubated with 15mM E-2-hexenal for 15
hours at 37C followed by reaction with Ellman’s reagent to detect free
Cys residues. The rate of detection of the thiol groups was 0.0004min-1.
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4.5 Cyanogen Bromide Digestion and HPLC Separation of HSA Fragments
Reduction and carboxymethylation followed by treatment with cyanogen bromide was
done to fragment HSA into smaller peptides in the hope that the primary location of α,βunsaturated aldehyde modification could be located. Cyanogen bromide cleaves on the
carboxyl side of methionine residues (Figure 4.32). Because the sequence of HSA is
known, it is possible to determine the location of fragmentation and calculate
approximate molecular weights of the peptide fragments that are produced after
treatment with CNBr. HSA has six methionine residues in its sequence, so we expect to
produce seven HSA peptide fragments ranging in size from 3.4kDa to 20.0kDa (Table
4.1).
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Figure 4.32: Reaction of cyanogen bromide cleaving a peptide chain at
the carboxy terminal end of a Methionine residue.
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Fragment Number
1
2
3
4
5
6
7

Residues Numbers
1 – 87
88 – 123
124 – 298
299 – 329
330 – 446
447 – 548
549 - 585

Molecular Weight (kDa)
9.4
4.1
20.0
3.4
13.5
11.6
4.0

Table 4.1: Table of expected HSA fragment locations and molecular
weights of the resulting peptides after treatment with CNBr.

The resulting peptides were separated on a reversed phase C18 HPLC column. The
method used to separate the fragments was modified from that published by
Campagnini et al. [8] and absorbance at both 224nm (peptide bonds) and 280nm
(aromatic amino acid residues) was monitored. The chromatogram matched with those
published previously in the literature, so fragment numbers could be assigned to each of
the peaks by comparison to literature separations (Figure 4.33). As expected, two of
the peaks with an absorbance at 224nm did not have any absorbance at 280nm
because two of the predicted fragments (fragments 2 and 7) do not have any aromatic
amino acid residues. The CNBr treated HSA fragments were run on a 20% separating
and 4% stacking SDS-PAGE gel (Figure 4.34, lane 2). Peptide fragments were
detected in the expected molecular weight range and there was no protein detectable
representing native HSA (~66kDa).
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Figure 4.33: Comparison of absorbance at 224nm and 280nm for CNBr
treated HSA after separation through a reversed phase C-18 HPLC
column.
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Figure 4.34: 4% Stacking and 20% separating SDS-PAGE gel of CNBr
treated HSA. Lane 1: Low molecular weight standards, Lane 2: Control
HSA, Lane 3: E-2-hexenal modified HSA, Lane 4: High molecular
weight standards.

The same procedure for reduction, carboxymethylation and CNBr treatment was used
for HSA that had been treated with E-2-hexenal, 4HNE, or 4ONE. Incubation of HSA
with 15mM E-2-hexenal or 6.4mM 4HNE was anticipated to produce a loss of one or
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more of the peaks in the chromatogram and / or the appearance of a new peak(s) that
would correspond to the inability of CNBr to fragment HSA in the same way as in
unmodified HSA due to cross-linking. The absorbance traces for unmodified HSA,
15mM E-2-hexenal modified HSA, and 6.4mM 4HNE modified HSA were overlaid for
comparison (Figure 4.35). The E-2-hexenal modified HSA was also run on a 20%
separating SDS-PAGE gel in order to ascertain the presence of protein fragments in the
same molecular weight range as the unmodified CNBr treated HSA (Figure 4.34, Lane
3). According to the SDS-PAGE gel, the E-2-hexenal modified CNBr treated HSA did
not fragment into peptides with the same molecular weights as the unmodified CNBr
treated HSA. Surprisingly, the modified CNBr treated HSA did not appear to fragment
at all, but rather migrated to a molecular weight that was so high that it did not enter the
separating gel. A lower percentage gel was run to see if a molecular weight could be
estimated for the E-2-hexenal modified CNBr treated HSA (Figure 4.36).

Absorbance (224 nm)

1.2
1
0.8
0.6
0.4
0.2
0
0

5

10

15

20

25

30

35

40

45

50

55

Time (minutes)

Figure 4.35: Overlay of HPLC chromatographs of unmodified (blue),
15mM E-2-hexenal modified (green), and 6.4mM 4HNE modified
(orange) CNBr treated HSA.
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Figure 4.36: 10% Separating and 4% stacking SDS-PAGE gel of CNBr
treated E-2-hexenal modified HSA (lane 1), molecular weight standards
(lanes 2 and 5), unmodified HSA (lane 3), and E-2-hexenal modified
HSA (lane 4).

Although the gel was overloaded, it was obvious that E-2-hexenal modified CNBr
treated HSA primarily migrates to a molecular weight that is higher than any of the
molecular weight markers (>205kDa). Comparison of modified and unmodified HSA
that had not been treated with CNBr (Figure 4.36, lanes 3 and 4) showed extensive
cross-linking in the aldehyde modified sample that was not observed in the unmodified
protein. The extensive cross-linking causes the E-2-hexenal modified CNBr treated
HSA to have a different elution profile at 224nm than the unmodified CNBr treated HSA.
In attempts to eliminate the extensive cross-linking, the concentration of 4HNE was
reduced to 1mM, the procedure was repeated and compared to the 6.4mM 4HNE
sample (Figure 4.37). Based on the elution time of the protein, it appears that
modification with a lower concentration of 4HNE results in less cross-linking than
modification with 6.4mM 4HNE. However, the cross-linking appears to be random and
a single point of aldehyde modification could not be located. The concentration of E-280

hexenal was also reduced to a 1:10 ratio (0.7mM HSA and 0.07mM E-2-hexenal). The
procedure was repeated and the resulting elution profiles were compared (Figure 4.38).
No difference was detected between the elution profiles of the unmodified and 0.07mM
E-2-hexenal modified HSA.
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Figure 4.37: Overlay of HPLC chromatographs of unmodified (blue),
1mM 4HNE modified (red) and 6.4mM 4HNE modified (green) CNBr
treated HSA.

1.6
Absorbance (224nm)

Absorbance (224 nm)

1.2

1.4
1.2
1
0.8
0.6
0.4
0.2
0
0

10

20

30

40

50

60

Time (minutes)

Figure 4.38: Overlay of HPLC elution profiles of unmodified (blue) and
0.07mM E-2-hexenal modified (orange) CNBr treated HSA.
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HSA was also modified with 4ONE and the modified protein was then reduced,
carboxymethylated and treated with CNBr so that the fragments could be separated
using the HPLC. Separation resulted in a new peak eluting at 37.4 minutes in the
elution profile (Figure 4.39). All of the other fragments are still observable (although
lesser in absorbance) and eluted at the same time as the unmodified CNBr treated
HSA. The difference chromatogram of unmodified CNBr treated HSA and 4ONE
modified CNBr treated HSA was plotted in order to determine the fragments most
affected by modification (Figure 4.40). The flow from the end of the HPLC column was
split so that half went through the UV detector and the other half went through a
fluorescence detector that was set to record excitation at 350nm and emission at
420nm, the settings that were used to monitor protein fluorescence development for
4ONE modified HSA. Protein fluorescence eluted at the same time as the peak
corresponding to the same elution time as fragments 1 and 5 in the unmodified CNBr
treated HSA and the new peak observed in the 4ONE modified CNBr treated HSA
(Figure 4.41).
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Figure 4.39: Elution profile of unmodified (blue) and 1mM 4ONE
modified (green) CNBr treated HSA. Arrow indicates the new peak that
elutes at 37.4 minutes.
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Figure 4.40: Difference chromatogram of unmodified CNBr treated HSA
minus spectra of 4ONE CNBr treated HSA.
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Figure 4.41: Elution profile of 1mM 4ONE modified CNBr treated HSA,
absorbance at 224nm (black) and fluorescence with excitation of 350nm
and emission of 420nm (blue).

4.6 MALDI-TOF Mass Spectrometry of Digested HSA
The appearance of a new peak in the elution profile of 4ONE modified CNBr treated
HSA lead to the use of MALDI-TOF mass spectrometry to try and determine the origin
of the new peak in the absorbance elution profile and the fluorescent peak. Fractions
from 4ONE modified CNBr treated HSA were collected for each of the peaks in the
elution profile according to retention time (Table 4.2). Fractions were also collected for
unmodified CNBr treated HSA according to the same retention times so that the
molecular weights of the new split peak could be compared to a control sample.
Fractions were collected for several runs of both the unmodified and 4ONE modified
CNBr treated HSA samples. Fraction 6 from the 4ONE modified CNBr treated HSA was
reanalyzed by HPLC in order to determine the purity of the peak collected (Figure 4.42).
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Fraction Number
1
2
3
4
5
6

Fragment Number
2
4
7
6
3
1, 5, new peak

Retention Time (min)
19.5 – 21.5
28.5 – 30.3
30.3 – 31.3
31.3 – 33.0
33.0 – 35.0
35.0 – 39.0

Table 4.2: Table of fraction number, corresponding fragment number
and retention time for 4ONE modified CNBr treated HSA. The fractions
of the separation were collected so that the peaks could be analyzed
using MALDI-TOF MS.
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Figure 4.42: Elution profile of Fraction 6 for 4ONE modified CNBr
treated HSA, absorbance at 224nm (black) and fluorescence excitation
350nm and emission 420nm (blue).

MALDI-TOF MS was taken for undigested, unmodified HSA to check the purity of the
albumin that we were working with (Figure 4.43). Expected masses of the HSA
monomer (66868) and dimer (133669) were detected. In order to determine the origin
of the masses detected in the subsequent spectra, it was necessary to compare our
values with those reported earlier in the literature by Campagnini et al. [8] (Table 4.3).
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Figure 4.43: Linear mode MALDI-TOF MS of unmodified, undigested
HSA.
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Fragment Number
1
2
3
4
5
6
7

Calculated (Da)
Homoserine
Homoserine Lactone
10041.2
4354.8
20699.3
3372.8
13905.9
11959.6

10023.1
4336.8
20681.3
3354.7
13887.9
11941.6
4097.6

MALDI Determined
(Da)
10022
4334
20704
3357
13902
11941
4097

Table 4.3: Table comparing expected molecular weights and actual
molecular weights of CNBr treated HSA MALDI-TOF MS from the work
of Campagnini et al. [8].

MALDI-TOF MS were compared for unmodified (Figure 4.44) and 4ONE modified
(Figure 4.45) CNBr treated HSA, Fraction 6. Unmodified HSA gave masses that
corresponded to Fragment 4 (3359), Fragment 2 (4344), Fragment 1 (10049), and
Fragment 5 (13932), with the most intense peaks for the expected Fragments 1 and 5.
4ONE modified HSA gave masses that correspond to Fragment 4 (3358), Fragment 2
(4342), Fragment 1 (10072), and Fragment 5 (13942). An additional mass of 20923
was detected which could reflect a H+ dimer or a new mass created from a cross-link of
two or more fragments due to aldehyde modification. A major difference between the
modified and unmodified samples was not detected in the molecular weight range that
would indicate cross-linking of fragments. A closer look at the lower molecular weight
range (3900 – 4700) yielded a change in the masses detected. Fraction 6 from
unmodified CNBr treated HSA had masses that corresponded to Fragment 7 (4099),
Fragment 2 (4341) and an additional peak with a mass of 4369 (Figure 4.46). Fraction
6 from 4ONE modified CNBr treated HSA gave a mass that corresponded to Fragment
2 (4339) however, the mass that corresponded to Fragment 7 was not observed (Figure
4.47).
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Figure 4.44: Linear mode MALDI-TOF MS of elution time that
corresponded to the fluorescent peak in 4ONE modified HSA (Fraction 6)
collected from unmodified CNBr treated HSA.
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Figure 4.45: Linear mode MALDI-TOF MS of fluorescent peak (Fraction
6) collected from HPLC separation of 4ONE modified CNBr treated HSA
fragments.
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Figure 4.46: Reflectron mode MALDI-TOF MS of fluorescent peak from
HPLC elution (Fraction 6 ) collected from unmodified CNBr treated HSA.
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Figure 4.47: Reflectron mode MALDI-TOF MS of fluorescent peak
collected from HPLC separation (Fraction 6) of 4ONE modified CNBr
treated HSA.

4.7 SDS-PAGE Gel Electrophoresis
The observation that higher molecular weight species that could be observed via SDSPAGE gel electrophoresis after incubation with an α,β-unsaturated aldehyde was
intriguing and needed to be investigated further. HSA was incubated with one of the
aldehydes and after a designated amount of time, an aliquot was removed and diluted
with SDS sample buffer to be run on an SDS-PAGE gel. E-2-hexenal (Figure 4.48),
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4HNE (Figure 4.49) and 4ONE (Figure 4.50) were all incubated with HSA in order to
monitor the development of molecular weight species larger than that of native HSA.
The first gel (Panel A in Figures 4.48, 4.49, and 4.50) was run overloaded with protein in
order to detect any new protein species that developed with increasing incubation time.
Later, the protein loading was decreased (Panel B in Figures 4.48, 4.49, and 4.50) so
that any mobility shift in the native HSA band could be detected.

A

B

Figure 4.48: SDS-PAGE gel electrophoresis of 0.7mM HSA incubated
with 30mM E-2-hexenal. Panel A; molecular weight markers (lane 1), 0
hours (lane 2), 2 hours (lane 3), 6 hours (lane 4), 10 hours (lane 5), 24
hours (lane 6). Panel B; before aldehyde addition (lane 1), molecular
weight markers (lane 2), 0 hours (lane 3), 2 hours (lane 4), 6 hours (lane
5), 10 hours (lane 6), 24 hours (lane 7).
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B

A

Figure 4.49: SDS-PAGE gel electrophoresis if 0.7mM HSA incubated
with 6.4mM 4HNE. Panel A; High loading of protein and Panel B, low
loading of HSA. Lane 1, before aldehyde addition; Lane 2, molecular
weight markers; Lane 3, 0 hours; Lane 4, 2 hours; Lane 5, 6 hours; Lane
6, 10 hours; Lane 7, 24 hours.
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B

Figure 4.50: SDS-PAGE gel electrophoresis if 0.7mM HSA incubated
with 1mM 4ONE. Panel A; High loading of protein and Panel B, low
loading of HSA. Lane 1, before aldehyde addition; Lane 2, molecular
weight markers; Lane 3, 0 hours; Lane 4, 2 hours; Lane 5, 6 hours; Lane
6, 10 hours; Lane 7, 24 hours.

Incubation of HSA with E-2-hexenal produced an increase in the intensity of the high
molecular weight bands observed on the SDS gel along with a decrease in the intensity
of the native HSA band. An increase in the high molecular weight species would
indicate an intermolecular cross-linking, therefore creating protein species that fall into
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the molecular weight range of a multiple of the molecular weight of native HSA. A
second gel was run with a lower loading of protein per well. This was done in an
attempt to visualize any mobility shift in the native HSA band that could be indicative of
intramolecular cross-linking. Accompanying the increase in the high molecular weight
species was the appearance and increase in intensity with time of a band that migrated
to an apparent molecular weight of 83kDa. The origin of this band is unknown, but it is
thought to be the result of a change in mobility of the native HSA band due to
intramolecular cross-linking. However, because this band is such a minor component of
the total protein, its origin was not investigated further. A similar trend in appearance of
high molecular weight species and the 83kDa band along with a loss of intensity of the
native HSA band with time was also observed for 4ONE modified HSA (Figure 4.50).

In contrast to the HSA samples incubated with E-2-hexenal and 4ONE, incubation with
4HNE produced an immediate increase in the high molecular weight species and an
immediate loss in the intensity of the native HSA band (Figure 4.49). No additional
changes were observed with increased incubation time and there was no indication of a
band migrating to an apparent molecular weight of 83kDa. The amount of increase in
the high molecular weight species was less for 4HNE than with the other two aldehydes.
Lowering the amount of protein loaded per well on the gel did not lead to any obvious
differences between the mobilities of the native HSA band. Because of the lower
loadings, the intensity of the minor protein components was not great enough to monitor
the development of the high molecular weight species or the species that migrates to
83kDa.
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4.8 Copper Binding to HSA
The binding of copper to HSA was studied in order to determine if modification by an
α,β-unsaturated aldehyde would prevent copper from binding to HSA, therefore
increasing the concentration of free copper in the system. HSA binds copper at one site
at the N-terminus of the sequence. If there is a change in the binding of copper to this
site, copper would be free to react with and cause damage in the system through free
radical reactions. Changes in copper binding were studied using isothermal titration
calorimetry (ITC) using the method of Zhang et al. [9, 10]. Titration experiments were
designed as competition experiments where HSA in tris buffer was titrated into a
solution containing copper(II)sulfate also in tris buffer. Experiments with unmodified
HSA gave approximately one binding site per albumin and a binding constant of Ka =
(5.1 ± 2.8) × 1012 (Figure 4.51).
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Figure 4.51: ITC of unmodified HSA titrated into copper sulfate.

Modification of HSA with 15mM E-2-hexenal before the ITC experiment eliminated
copper binding (Figure 4.52). Decreasing the concentration of E-2-hexenal to 1mM also
eliminated all copper binding to HSA (data not shown). However, incubation of HSA
with 1mM 4ONE prior to titration with a copper(II)sulfate solution resulted in fewer
copper binding sites (0.4 per molecule) which suggests modification of only some of the
copper binding sites (Figure 4.53). The binding affinity for copper to 4ONE modified
HSA was slightly lower than unmodified HSA, Ka = (1.0 ± 0.8) × 1011. Increasing the
concentration of 4ONE to 2mM and repeating the procedure resulted in complications
because of the amount of ethanol needed to solubilize the 4ONE. This made the buffer
compositions in the ITC cell and syringe different making the heats of dilution and
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injection greater than zero. Therefore, the heat observed in the experiment was not
only the heat of binding as it had been in the prior experiments.
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Figure 4.52: ITC of 15mM E-2-hexenal modified HSA titrated into
copper(II)sulfate.
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Figure 4.53: ITC of 1mM 4ONE modified HSA titrated into
copper(II)sulfate.
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Chapter 5: Discussion

5.1 Time Course of Protein Fluorescence
Protein fluorescence was found to develop with time for HSA incubated with α,βunsaturated aldehydes. We expect that the cross-link that develops is the result of a
Michael addition followed by a Schiff base formation [1]. According to these
mechanisms, the cross-linked structure would be similar to that shown in Figure 5.1.
After the formation of the cross-link, the structure is expected to rearrange to form a
cyclic fluorophore [1] (Figure 5.2).

Protein

Protein

NH

N
H

R

Figure 5.1: Structure of cross-linked structure that is expected from the
Michael addition and Schiff base formation that results from reaction of a
nucleophilic protein residue (Lysine side chain) with an α,β-unsaturated
aldehyde.

Protein
N
H11C5
HO

N
Protein

Figure 5.2: Structure of expected fluorophore that rearranges after
cross-links develop from the reaction of necleophillic amino acid residues
with an α,β-unsaturated aldehyde. Adapted from the structure proposed
by Tsai et al. [1] from the study of the fluorophore developed from 4HNE
and lysine.
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E-2-hexenal and 4ONE produced an increase in protein fluorescence with time. Protein
fluorescence developed with time for both aldehydes. The development of protein
fluorescence was measured as a pseudo first order reaction because the concentration
of aldehyde present was in excess over the concentration of protein, so we assume that
the aldehyde concentration is not changing significantly over the course of the
experiment. It is not a great surprise that 4ONE reacts faster than E-2-hexenal because
of the additional carbonyl group on 4ONE that is not present in E-2-hexenal. The extra
carbonyl group makes the double bond in 4ONE accessible from either side in 4ONE,
which is not possible in E-2-hexenal. Also, more important is the difference in hydration
of a ketone versus an aldehyde. Hydration of the aldehyde in 4HNE will result in the
loss of an α,β-unsaturated carbonyl. Ketones are hydrated to a very small extent (less
than 1%); therefore, 4ONE will keep its ability to react as a Michael acceptor towards
protein nucleophiles [2]. The time course for protein fluorescence development for both
E-2-hexenal and 4ONE were fit to second order exponentials. This strongly implies
there are at least two classes of lysine residues in HSA that differ in reactivity. It is
possible that there are more classes of reactive lysine residues, however, I fit the data
to the simplest reasonable model. One possible explanation for two reactive classes of
Lysine residues could be differences in the amount of surface exposure of the Lysine
side chain. The lysine residues that are surface exposed would be predicted to react
first with the aldheydes. Those lysine residues that are less surface exposed should
react more slowly, thus resulting in a slower rate of fluorescence development. The
percent surface exposure of the nitrogen in the lysine side chain was calculated using
the free-ware program PROtein Volume Evaluation (PROVE,
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http://www.ucmb.ulb.ac.be/SCMBB/PROVE). Thirteen of the fifty-eight lysines in HSA
are in the 90th percentile of surface exposure. Differences in the degree of surface
exposure (Table 5.1) suggest that there are several different classes of reactive lysine
residues.
Surface Exposure Percentile
90th percentile
80th percentile
70th percentile
60th percentile
50th percentile
40th percentile
30th percentile
20th percentile
10th percentile
< 10th perentile

Number of lysine Residues
13
8
3
7
3
9
3
3
5
4

Table 5.1: Table of number of lysine residues in HSA compared to the
surface exposure of the side chain nitrogen. Lysines in the higher
percentiles are more surface exposed than those in the lower
percentiles.

Protein fluorescence of 4HNE modified HSA did not develop gradually over time.
Instead, the small amount of protein fluorescence that formed developed immediately
after the addition of 4HNE and did not increase further for the next 24 hours. I believe
that the fluorescence that developed was the result of a complete and immediate
reaction of 4HNE with HSA. Any reaction that would be expected with a second, less
reactive class of Lysine residues (as seen with E-2-hexenal and 4ONE) might not be
observed because the aldehyde on 4HNE will become hydrated, causing 4HNE to lose
its ability to react with protein nucleophiles and produce the fluorophore. Comparison of
identical concentrations of 4HNE and E-2-hexenal incubated with HSA suggests that
protein fluorescence develops via different pathways for each aldehyde. Addition of
successive amounts of 4HNE resulted in an increase in the protein fluorescence
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followed by no additional changes, while additional amounts of E-2-hexenal caused the
rate of protein fluorescence development to increase proportionally to the amount of E2-hexenal added.

The protein fluorescence that develops from incubation of an α,β-unsaturated aldehyde
with HSA has characteristics that are similar to the fluorophore that is found with
lipofuscion and ceroid. Lipofuscion and ceroid have been found to accumulate in
postmitotic cells with age [3]. Fluorescent properties similar to that of lipofuscion and
ceroid have been observed upon incubation of α,β-unsaturated aldehydes with Lysine
derivatives [1, 4, 5]. The similarities between the fluorescence properties characterized
for α,β-unsaturated aldehyde modified lysine derivatives strongly suggest that the
fluorescence properties observed in HSA are the result of modification by α,βunsaturated aldehydes produced from lipid peroxidation. Similar properties have also
been observed in serum samples of elderly subjects where HSA has been isolated as a
major fluorescent component [6]. Therefore, HSA may provide a pathway for removal
or neutralization of the by-products of lipid peroxidation so that they cannot induce
further damage in the body. If, in fact, HSA serves as a potential “sink” for the byproducts of lipid peroxidation, it is necessary to determine the effects, if any, on the
structure and function of HSA that could compromise the physiological functioning of
HSA following such modification.
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5.2 DAUDA and DNS Binding
One of the goals of this project was to show that modification of HSA by α,βunsaturated aldehydes would cause a change in the medium-chain fatty acid binding
sites that would prevent fatty acids from binding to these sites. One way to detect
changes in the medium-chain fatty acid binding sites was to monitor binding of a probe
to the sites of interest. DAUDA purportedly binds to three sites on HSA [7]. These sites
are the medium-chain fatty acid (bilirubin) binding sites. DAUDA binds to these sites
with different affinities; there are reportedly one high affinity site and two sites with lower
but approximately equal affinity [7]. The maximum fluorescence emission of DAUDA
increases in intensity when DAUDA is bound to a site on HSA. We used the increase in
fluorescence emission to detect changes in the ability of DAUDA to bind to aldehyde
modified HSA. The assumption made was that a diminishment of DAUDA enhanced
fluorescence reflected loss of DAUDA binding to the sites on HSA. Because aldehyde
modified HSA exhibited a lower fluorescence emission with DAUDA than did equivalent
concentrations of unmodified HSA and DAUDA, we concluded that the α,β-unsaturated
aldehydes caused a modification to the DAUDA binding sites. This modification
prevented the DAUDA from binding to the same sites as in unmodified HSA, therefore
causing the DAUDA enhanced fluorescence to be less with the modified HSA.

Although protein fluorescence developed more rapidly in 4ONE modified HSA (k1 = (3.9
± 0.97) % 10-2 min-1 and k2 = (5.6 ! 3.6) % 10-3 min-1) than for E-2-hexenal modified HSA
(k1 = (1.2 ! 0.28) % 10-2 min-1 and k2 = (3.7 ! 1.2) % 10-4 min-1), the rates for the loss of
DAUDA binding fluorescence were very similar for both aldehydes (k1 = (1.6 ± 0.35) %
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10-2 min-1 and k2 = (7.8 ! 8.8) % 10-4 min-1 for E-2-hexenal modified and k1 = (4.5 ± 1.6)
% 10-2 min-1 and k2 = (6.1 ! 3.2) % 10-3 min-1 for 4ONE modified HSA). Comparison of
the rates of protein fluorescence development and rates of loss of DAUDA binding
fluorescence suggest that these processes are correlated. A small amount of DAUDA
binding fluorescence was lost for 4HNE modified HSA, however, the fluorescence was
lost immediately after the addition of 4HNE and additional fluorescence was not lost
during the next 24 hours. It is not surprising that the extent of DAUDA binding
fluorescence was greater with 4ONE than with E-2-hexenal given that the same trend
was observed for the development of protein fluorescence. Because of the apparent
loss of DAUDA binding site(s), I attempted to quantitate the number of binding sites that
are lost from aldehyde modification.

Scatchard analysis allows determination of the number of ligand binding sites and
binding association constant (Ka) by plotting [bound ligand] / [receptors] on the x-axis
and [bound ligand] / [free ligand] on the y-axis. The plot should yield a straight line for
each class of binding sites with the x-intercept being the number of ligand binding sites
and the slope of the line representing –Ka. We attempted to generate Scatchard plots
as Wilton [7] did to determine if a loss of the number of binding sites could be
demonstrated for aldehyde modified HSA. Wilton [7] generated Scatchard plots by
assuming that a maximum fluorescence was obtained in the presence of “excess
albumin” and represented complete binding of DAUDA and that the amount of DAUDA
bound is proportional to the relative fluorescence intensity. However, Wilton [7] did not
specify the concentration of albumin corresponding to “excess albumin”. In order to
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analyze my fluorescence data as Scatchard plots, it was necessary to measure the
fluorescence of DAUDA in the presence of excess HSA, when all of the DAUDA is
bound. Titrations of HSA into a fixed amount of DAUDA did not give the expected
fluorescence behavior. Based on Wilton’s results [7], it was expected that the
fluorescence emission would increase as the DAUDA bound to HSA and once all of the
DAUDA has bound to the HSA, the fluorescence would reach a plateau, which would
remain constant regardless of how much excess HSA was added. Instead, the
fluorescence increased until a maximum was reached and then the fluorescence
steadily diminished with increasing HSA (Figure 4.9). Because of the inability to
measure a maximum fluorescence value, it was impossible to generate Scatchard Plots
from the DAUDA fluorescence data.

Because of the complications of quantitating the number of binding sites with the probe
DAUDA, another fluorescent probe, 5-(Dimethylamino)naphthalene-1-sulfonic acid
(DNS), was investigated. Like DAUDA, DNS also binds to the medium-chain fatty acid
binding sites of HSA. However, DNS only binds to two sites, one with high-affinity, and
one with lower-affinity. Because DNS binds to fewer binding sites, our hope in using
DNS was that it would lead to fewer complications in analysis of fluorescence binding
data and information about aldehyde modification could be obtained.

Fixed concentrations of DNS were titrated with HSA until a maximum fluorescence was
obtained. Once maximum fluorescence was reached, it was assumed that all of the
DNS was bound to a site(s) on HSA. The yield of maximum fluorescence was
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approximately half for E-2-hexenal modified HSA compared to unmodified HSA. Based
on the fluorescence yield we assumed that approximately one DNS binding site was lost
upon modification by E-2-hexenal. The titration data from three different concentrations
of DNS were analyzed as Scatchard plots. In contrast to the DAUDA titrations,
additional amounts of HSA to DNS did yield a stable fluorescence plateau. Knowing the
maximum fluorescence allowed the calculation of a ratio of bound DNS to free DNS and
enabled Scatchard plots of the titration data. Scatchard analysis of control HSA gave
DNS binding results that agreed with those published by Doody et al., (Kd1 = 2 × 10-7M,
Kd2 = 3.3 × 10-6M) [8]. DNS bound to unmodified HSA at two sites, one with high affinity
(Kd1 = (2.6 ± 1.2) × 10-7 M) and one with lower affinity (Kd2 = (1.7 ± 0.9) × 10-6 M).
Based on the fluorescence titration results, where the maximum fluorescence was
significantly less for E-2-hexenal modified HSA, the expected result of the Scatchard
analysis was that one of the DNS binding sites would be lost because of aldehyde
modification. Therefore, it was surprising when Scatchard analysis indicated no loss of
DNS binding sites and an apparent enhancement in the DNS binding affinity to both
sites, Kd1 = (3.5 ± 3) × 10-8 M, and Kd2 = (4.5 ± 1.5) × 10-7 M.

One possibility to explain no loss of binding sites and an increase in DNS binding affinity
is that modification by E-2-hexenal causes a change in the structure of HSA. The
change in structure does not allow DNS to bind with the same affinities as it did in
unmodified HSA. DNS purportedly binds to the medium-chain fatty acid sites on HSA
[8]. The exact locations of the DNS binding sites are unknown, however crystal
structures of HSA complexed with long- and medium-chain fatty acids have been solved
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[9, 10]. Curry et al. [10] identified five binding sites on HSA for myristic acid (C14:0).
The carboxylate groups of the bound fatty acids in each of the five sites formed ionpairs with arginine or lysine residues and hydrogen bonds with serine or tyrosine
residues [10, 11]. Specifically, Curry et al. [10] identified Lys525 as the “anchor” for the
carboxylate end of one of the myristate molecules while the methylene tail extended into
the hydrophobic tunnel. A few years later, Bhattacharya et al. [9] confirmed that Lys525
played an important role in the binding one myristate molecule to HSA. However,
Bhattacharya et al. [9] also expanded the lengths of fatty acids that were studied and
identified additional fatty acid binding sites on HSA. Lys351 was identified as being one
of the residues possibly involved in binding medium-chain fatty acids to site six on HSA
[9]. They also identified a seventh binding site for medium and long chain fatty acids
which had several basic residues (Lys199, Arg218, Arg222, His242, and Arg257) close
to the carboxylate head-group, however, they could not be definitive about which
residues were involved with holding the fatty acid in place [9]. Also identified were sites
eight and nine, which were mainly occupied by C10:0 fatty acids [9]. Lys195 and
Lys199 are involved with site eight and Lys190, Lys432, and Lys436 are involved in site
nine [9].

It is possible that one of the lysine residues (Lys525, Lys351, Lys199, Lys195, Lys190,
Lys432, and Lys436) identified by Curry et al. [10] and Bhattacharya et al. [9] as having
involvement in the fatty acid binding sites are susceptible towards modification.
Modification of a lysine residue involved in a fatty acid binding site could induce a
conformational change in the structure of HSA, therefore causing the fatty acid to be
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“anchored” into the site by coordination through another basic amino acid residue in the
vicinity of the opening of the binding site. For example, if Lys199 is modified, a fatty
acid molecule could bind to site seven differently. A modification to Lys199 could cause
a conformational change that would cause some of the other basic residues in the
vicinity (Arg218, Arg222, His242, and Arg257) to become involved in binding of the fatty
acid to the site.

In an attempt to further investigate differences in DNS binding sites for unmodified and
E-2-hexenal modified HSA, additional titrations were performed in which the
concentration of HSA was held constant and DNS was added until fluorescence
reached a plateau. Once the plateau of fluorescence was reached, it was assumed that
DNS binding to HSA was saturated and the data were fit to straight lines. Unmodified
HSA again showed the presence of two binding sites of unequal affinity while E-2hexenal modified HSA indicated the presence of two DNS binding sites of
approximately equal affinity. Equilibrium dialysis experiments were designed so that a
direct measurement of free and bound DNS could be obtained for Scatchard analysis.
These experiments did not prove successful because of apparent binding of DNS to the
dialysis membrane.

Time courses for the loss of DNS binding were also investigated. The relative rates for
loss of DNS binding agreed with the relative rates for development of protein
fluorescence with incubation of HSA with an α,β-unsaturated aldehyde. E-2-hexenal
modification of HSA resulted in loss of DNS binding fluorescence with most of the
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change occurring over the course of the first two hours of incubation. 4ONE
modification of HSA resulted in a more rapid rate of loss of DNS binding fluorescence
than E-2-hexenal modified HSA. 4HNE modified HSA lost DNS binding fluorescence
immediately and no additional loss of DNS binding fluorescence was observed over the
course of 24 hours. This trend in loss of DNS binding fluorescence was not surprising
based on the structures of the aldehydes used. One would expect 4ONE and 4HNE to
modify HSA faster then E-2-hexenal based on literature results from α,β-unsaturated
aldehyde modification of lysine derivatives and small peptides containing lysine
residues [2, 12-15].

5.3 Quantitation of Cysteine Residue
HSA has 35 cysteine residues in its sequence. 34 of the cysteines participate in 17
disulfide binds that act to stabilize the structure of the protein. Cys34 sits in a
hydrophobic crevice that is approximately 9.5 – 10 Å deep [16]. Because DAUDA and
DNS binding fluorescence were lost so much faster that protein fluorescence
developed, we anticipated that the rapid loss of DAUDA and DNS binding fluorescence
might be the result of modification of a residue other than Lys. Doorn et al. [2] found
that the order of reactivity for amino acid residues modified by 4ONE or 4HNE was
Cys>>His>Lys (>Arg in 4ONE). Ellman’s reagent was used to quantitate Cys34 in
unmodified and E-2-hexenal modified HSA. Based on the results of Doorn et al. [2], the
hypothesis is that free Cys 34 will not be detected in the modified HSA.
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The normal reaction between free thiols and Ellman’s reagent is shown in Figure 5.3.
Thiol groups react with Ellman’s reagent in a 1:1 ratio at pH 8.1. The product, 3carboxylato-4-nitrothiophenolate, has a maximum absorbance at 412nm. Reaction of
unmodified HSA with Ellman’s reagent detected 0.3 thiols per albumin. This was a
surprising result because it was expected that there would be 1 thiol per HSA because
of the one free Cys residue. Carballal et al. [17], however, studied Cys34 in HSA and
found that approximately 74% of the time, the free thiol was likely to form sulfenic acid
that is unreactive towards Ellman’s reagent. Cys34 also reacts with other thiols in the
system such as glutathione, making Cys34 unreactive towards Ellman’s reagent. This
could also explain detecting a substoichiometric ratio of thiols per HSA. E-2-hexenal
modified HSA was also allowed to react with Ellman’s reagent. If Cys34 is modified by
E-2-hexenal, then it is presumed that a lower thiol content would be measured.
Surprisingly, 0.4 thiols were detected for every E-2-hexenal modified HSA. However,
the rate of reaction of the free thiol with Ellman’s reagent was much slower for the E-2hexenal modified HSA (k = 0.004min-1) than for unmodified HSA (k = 0.10min-1).
Because approximately the same number of thiol groups was determined per HSA for
the modified and unmodified HSA, Cys 34 must not be modified by E-2-hexenal.
Instead, modification in the vicinity close to Cys34 may diminish solvent accessibility,
causing the rate of reaction to be slower. Five lysine residues are located within 12.5Å
of Cys34 (Figure 5.4). The distances between the Lys residues closest to Cys34 can be
found in Table 5.2. It is likely that Lys41, lys73, Lys106, Lys136, and/or Lys137, which
are all within 12.5 Angstroms of Cys34 are susceptible to modification by E-2-hexenal.
Modification of one or more of these Lysine residues could result in a conformational
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change in the structure of HSA which could result in burying Cys34 further from the
surface of the protein. It is also possible that two lysine residues, most probably Lys41
and Lys73, are close enough to each other (separated by 6.2 Angstroms) to be crosslinked by E-2-hexenal. Any conformational change occurring in the vicinity of Cys34
could lead to the burial of Cys34 making its reaction with Ellman’s reagent slower.
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Figure 5.3: Reaction of Ellman’s reagent with a free thiol to produce a
mixed disulfide and 3-carboxylato-4-nitrothiophenolate, which has a
maximum absorbance at 412nm.
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Figure 5.4: Partial structure of HSA showing the only free Cys residue
and Lys residues within 12.5 Angstrom of Cys34. The crystal structure
was obtained from the Protein Data Bank, number 1ao6.

First Lysine
41
136
41
73
41
73
41
73
106
106

Second Lysine
73
137
136
136
137
106
106
137
136
137

Distance (Angstrom)
6.2
11.6
14.6
16.1
17.4
21.1
21.4
21.9
22.0
22.8

Table 5.2: Table of distances between Lysine residues that are within
12.5Å of Cys34. Residue pairs are arranged from shortest distance to
longest distance between Lysine residues.

5.4 Cyanogen Bromide Digestion and HPLC Separation of HSA Fragments
Cyanogen bromide cleaves proteins on the carboxy terminal side of methionine
residues. HSA has a total of six methionine residues in its sequence, so cleavage at
these residues will yield seven polypeptides ranging in size from 3.4kDa to 20.0kDa.
The method of Campagnini et al. [18] was used whereby the protein was reduced,
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carboxymethylated and then cleaved at the methionine residues with CNBr treatment.
Unmodified CNBr treated HSA separated into the expected fragments as determined by
comparison of the elution profile with those previously published [18].

0.7mM HSA was incubated with 15mM or 0.07mM E-2-hexenal for two hours at 37ºC
prior to reduction, carboxymethylation and treatment with CNBr. HSA has 58 lysine
residues in its sequence. The assumption that is made is that E-2-hexenal reacts with
lysine residues to produce an intramolecular or intermolecular fluorescent cross-link
between two lysine residues. Incubating HSA with these amounts of E-2-hexenal gave
a lysine to E-2-hexenal molar ratio of 2 ⅔ to 1 for 15mM E-2-hexenal and approximately
570 to 1 for 0.07mM E-2-hexenal. No difference was observed in the elution profile for
unmodified and 0.07mM E-2-hexenal CNBr treated HSA. This indicates that the
primary site of modification does not cause a disruption in the ability of CNBr to cleave
at the methionine residues. However, increasing the concentration of E-2-hexenal to
15mM causes extensive cross-linking as observed by a high molecular weight species
that did not enter the separating gel of an SDS-PAGE gel and a mass of protein that did
not separate into fragments following elution through the HPLC column. It is presumed
that after incubation with E-2-hexenal, lysine residues in the protein sequence have
been modified. Because of constraints in the secondary and tertiary structure of the
protein, the formation of cross-links could be limited. Upon reduction and
carboxymethylation, the secondary and tertiary structure of HSA is relaxed. Lysine
residues that were singly modified by E-2-hexenal would be allowed to come into
contact with unmodified Lysine residues. This would increase the probability of forming
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Schiff bases. This has the potential to lead to an extensively cross-linked protein
structure that would be unaffected by CNBr treatment and could explain the extensively
cross-linked species observed on the SDS-PAGE gels.

Similar results were observed for 4HNE modified CNBr treated HSA samples. 6.4mM
4HNE modified CNBr treated HSA and 1mM 4HNE modified CNBr treated HSA both
resulted in peptides that did not separate into fragment peaks. Incubation with the lower
amount of 4HNE did produce protein that eluted with the same retention time as
unmodified CNBr treated HSA, however, individual peptide fragment peaks were not
identifiable. The inability of individual fragment peaks to be identified after 4HNE
modification again suggests extensive cross-linking caused by the aldehyde to make
CNBr treatment ineffective.

The modified CNBr treated protein eluted over the same retention time range as
fragments 6, 3, and 1+5 in the unmodified CNBr treated elution profile. This was an
interesting observation and led to the speculation that the modification caused by high
concentrations of E-2-hexenal or 4HNE could be due to cross-linking of fragments 6, 3,
1, and 5 causing the cross-linked fragments to elute at approximately the same time as
the individual fragments. In order to investigate this, the distances between the
nitrogens in the lysine side chains were calculated from the crystal structure of HSA
from the Protein Data Bank (ID number 1ao6) [19]. The distances between the
nitrogens in the lysine side chains were calculated using Molecular Operating
Environment (MOE) [20] (Table 5.3). The closest lysine distances are between lysine
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residues that would be in fragments 3, 5, 1, and 6 of CNBr treated HSA. This leads to
the assumption that the most probable cross-links between lysine residues would arise
from cross-links involving fragments 3, 1, 5, and 6.

Distance (Angstrom)
5.35
5.4
5.71
6.13
6.22
6.85
6.89
6.98
7.8
7.88
8.64
8.73
8.98
9.36
9.73
9.83
10.02

First Lysine
190
20
436
20
41
402
195
225
323
323
359
413
573
190
159
262
274

Fragment #
3
1
5
1
1
5
3
3
4
4
5
5
7
3
3
3
3

Second Lysine
432
136
439
51
73
545
199
274
351
351
372
541
574
519
162
286
444

Fragment #
5
3
5
1
1
6
3
3
5
5
5
6
7
6
3
3
5

Table 5.3: Table of the distances between the closest ε-nitrogen in
lysine side chains of HSA. Residue number was used to determine the
CNBr fragment.

Modification of HSA with 1mM 4ONE followed by treatment with CNBr lead to
fragmentation of the protein that was very similar to the elution profile of unmodified
CNBr treated HSA. The similarities between the elution profiles are most likely due to
an absence of the formation of cross-links between Lysine residues in different CNBr
fragments. However, there was one obvious difference in the elution profile for 1mM
4ONE modified CNBr treated HSA; the peak that eluted at the same retention time as
Fragments 1+5 in unmodified CNBr treated HSA was split for the modified protein.
There also appears to be a decrease in the intensity of fragment peak 3 in 4ONE

116

modified CNBr treated HSA, as compared to the relative intensities of the peaks in
unmodified CNBr treated HSA. Based on the relative proximity of lysine residues in
fragments 1, 3, and 5, it is possible that 4ONE induces cross-linking between these
fragments that is apparent in the elution profile of 4ONE modified CNBr treated HSA.

The HPLC was reconfigured so that the flow coming off of the column passed through
the UV detector followed by a fluorescence detector. This way, the location of the
protein fluorescence (excitation 350nm, emission 420nm) could be assigned to one of
the fragment peaks in the elution profile. After correcting for the delay between the two
detectors, all of the protein fluorescence eluted with the split peak. This is very exciting
because it means that all of the fluorescence formed due to the modification of 4ONE
with HSA is located in one peak in the elution profile. It was necessary to try and find
the source of the fluorescence development, so the 4ONE modified CNBr treated HSA
was run through the same method as before and individual peaks were collected based
on retention time.

MALDI-TOF MS was used in order to determine the molecular weights of the
components in the last peak in the elution profile of CNBr treated HSA. Fraction 6
(containing fragments 1 and 5) from unmodified CNBr treated HSA gave predominant
masses that correspond to the expected masses of fragments 1, 2, 4, and 5. It was
expected to see fragments 1 and 5, however it was a surprise to see masses that
correspond to fragments 2 and 4. The presence of fragments 2 and 4 in this fraction
suggests that the separation is not very clean. The same analysis was done for fraction
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6 of 4ONE modified CNBr treated HSA, the fraction that contains the protein
fluorescence. Masses from this peak also correspond to fragments 1, 2, 4, and 5.
There was no peak with a mass corresponding to a cross-linking of two of the
fragments, as expected. The masses observed were compared to the calculated
masses of the fragments (Table 5.4).

Fragment
Number

Calculated (Da) [18]
Homoserine

1
2
4
5

10041.2
4354.8
3372.8
13905.9

Homoserine
lactone
10023.1
4336.8
3345.7
13887.9

MALDI Determined (Da)
Unmodified
Fraction 6
10049
4344
3359
13932

4ONE Modified
Fraction 6
10072
4342
3358
13942

Table 5.4: Comparison of calculated fragment sizes and MALDI
determined fragment sizes from the last peak eluted from the HPLC
elution profile of CNBr treated HSA.

Closer inspection of the low mass range did indicate a difference between the two
samples. MALDI-TOF MS was run again in reflector mode for the two samples in
question. Reflector mode was used so that a more accurate mass could be determined
for each of the species present. Because the most obvious differences between the two
spectra were in the low range, only masses between 3900 and 4700 Da were detected.
Comparing the intensities of the peaks in the spectra did show a loss of one of the
fragments in the 4ONE modified CNBr treated HSA (Table 5.5). Detecting only low
range molecular weights from fraction 6 of unmodified CNBr treated HSA gave masses
that correspond to fragment 2, 4, and 7, while 4ONE modified CNBr treated HSA had
masses that correspond to only fragments 2 and 4. The main difference between
fraction 6 components in unmodified and 4ONE modified CNBr treated HSA was that
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fragment 7 was present in the unmodified sample, but was clearly absent in 4ONE
modified HSA.

Fragment
Number

Calculated (Da) [18]
Homoserine

2
4
7

Homoserine
Lactone
4336.8
3354.7

4354.8
3372.8
4097.6

MALDI Determined (Da)
Unmodified
Fraction 6
4341
3356
4099

4ONE Modified
Fraction 6
4340
3354
NP

Table 5.5: Table of calculated fragment sizes and MALDI determined
fragment sizes from fraction 6 of unmodified and 4ONE modified CNBr
treated HSA. Molecular weights were determined from reflector mode
MALDI-TOF MS scanning from 3900 – 4700 Da. NP = none present.

5.5 SDS-PAGE Analysis of α,β-Unsaturated Aldehyde Modification of HSA
After CNBr treatment of HSA did not yield fragment sizes that were smaller than native
HSA, the time course of high molecular weight species was investigated. Incubation of
HSA with E-2-hexenal and 4ONE produced an increase in the high molecular weight
species that represented intermolecular cross-linking, the formation of dimers and
higher order olgimers of HSA. Also observed was the formation of a very minor
component that migrated to a molecular weight of approximately 83kDa. The origin of
this component was of interest. It was anticipated that a slight variation of the migration
of the native HSA peak could be observed due to intramolecular cross-linking which
would slightly alter the shape of the unfolded protein and therefore, affect the migration
distance on the gel [21, 22]. Ross and McIntosh [21, 22] have noted that intramolecular
cross-linking causes the appearance of a species that has a higher molecular weight
(115 kDa) than the native protein band in Ca2+-ATPase (110 kDa). This explained the
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decrease in mobility by the location of the covalent intramolecular cross-links formed.
Under normal conditions, reduced proteins will migrate through the SDS-PAGE gel in a
rod-like shape. If an intramolecular cross-link occurs, a loop in the protein sequence is
formed that prevents complete reduction of the protein structure. This would cause the
protein structure to have a different shape that would have increased frictional
resistance and would migrate to an apparent increased molecular weight [22]. The
large apparent change in molecular weight observed for α,β-unsaturated aldehyde
modified HSA compared to native HSA migration was approximately 15 kDa, which is
consistent with the change in mobility detected by Ross [21]. The appearance of the 83
kDa band in SDS-PAGE gels of α,β-unsaturated aldehyde modified HSA could be
explained by the formation of an intramolecular cross-link causing a change in the
protein structure that would migrate to an apparent molecular weight of 83 kDa.

SDS-PAGE gels of a time course of E-2-hexenal modified HSA show an increase in the
83kDa species that increases slightly and then reaches a plateau after 6 hours. The
high molecular weight species gradually increase in intensity and the native HSA band
decreases in intensity for the entire 24-hour incubation period (Figure 5.5). The same
general trend was observed for the time course of 4ONE modified HSA (Figure 5.6).
4HNE modified HSA did not indicate the development of an 83kDa band, however, the
species could still be present but at concentrations that could not be observed on the
SDS-PAGE gel (Figure 5.7). Also observed was an immediate increase in the high
molecular weight species and decrease in the intensity of the native HSA band upon
addition of 4HNE. The rapid change observed in the SDS-PAGE gels for 4HNE
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modified HSA is not surprising given the immediate development of protein
fluorescence and loss of DNS binding fluorescence also observed with 4HNE modified
HSA.
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Figure 5.5: Time course of percent band composition for 0.7mM HSA
incubated with 30mM E-2-hexenal. High molecular weight ((), native
HSA (*), and 83kDa species (»).
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Figure 5.6: Time course of percent band composition for 0.7mM HSA
incubated with 1mM 4ONE. High molecular weight ((), native HSA (*),
and 83kDa species (»).
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Figure 5.7: Time course of percent band composition for 0.7mM HSA
incubated with 6.4mM 4HNE. High molecular weight (() and native HSA
(»).

Additional gels were run with lower protein loadings per well. This was done to
determine if overloading the gel blurred the resolution therefore masking slight
variations in migration of the native HSA band. No changes in migration were observed
with decreased protein loading for any of the α,β-unsaturated aldehydes studied. This
is probably the result of the broad migration of the native HSA band that has been
observed for every SDS-PAGE gel run for this research.

It is expected that modification of Lysine residues in HSA by α,β-unsaturated aldehydes
would cause the pI to be lower than that of native HSA. Isoelectric focusing gels were
attempted to see if a change in the pI of HSA could be detected. Precast isoelectric
focusing gels were purchased from Bio-Rad with a pI separation range of 3-8. No
differences in the focusing point were observed for unmodified or aldehyde-modified
HSA. The isoforms of native HSA were not separated probably because of the large pI
range of the gel used.
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5.6 Isothermal Titration Calorimetry
HSA has one copper binding site at the N-terminal end of the sequence [16]. The
binding affinity constant for copper binding to HSA is very high and therefore difficult to
accurately measure. Reported values for the KA of copper binding to albumin have
ranged from log KA of 11.2 to 16.2 [16, 23, 24]. Copper(II) is coordinated to HSA in a
square planar coordination to the first three amino acids (Asp, Ala, and His) of HSA [25].
Copper(II) is therefore coordinated to the N-terminal amine, the first two deprotonated
amides, and the imidazole from the His3 residue [25]. Changes in the ability of HSA to
bind copper(II) are important because if copper is left free in the system, it is capable of
causing oxidative damage [26]. Therefore, under normal conditions, HSA acts in an
antioxidant capacity to rid the system of free copper(II). Modification of the ability of
HSA to bind copper(II) due to modification by lipid peroxidation derived α,β-unsaturated
aldehyde would compromise the ability of HSA to act as an antioxidant.

Zhang et al. [25, 27] have developed a method to measure the binding of copper(II) to
HSA using isothermal titration calorimetry (ITC). They used a borate buffer at pH 9.2
with 100mM Tris to act as the competing ligand for the metal ion. I used the method of
Zhang et al. [25] to perform initial experiment titrations that confirmed copper(II) was
binding to one site on HSA with an affinity of log KA 12.8 which was in agreement with
the reported value for this titration (log KA 13.8 [25]).

123

HSA was incubated with 15mM E-2-hexenal prior to the titration experiment. ITC
experiments showed a total loss of copper(II) binding to modified HSA (Figure 4.50).
The loss of binding was determined by comparison of my results to the work of Josè et
al. [28] who used ITC experimentation to show the loss of metal ion binding to PuvII
Restriction Endonuclease. A complete loss of copper(II) binding was also observed for
1mM E-2-hexenal modified HSA. In contrast, incubation of HSA with 4ONE prior to the
TIC experiment gave a slight decrease (0.4 per molecule) in the number of copper
binding sites per HSA molecule. It is possible that the 4ONE is either directly modifying
a residue close to the copper binding site to prevent copper binding, or that cross-linking
of the protein induced by 4ONE is burying the copper binding site also preventing
copper binding. Regardless of the mechanism of modification and the site modified, it is
apparent that α,β-unsaturated aldehydes inhibit copper(II) from binding to HSA, thus,
potentially allowing higher concentrations of free copper molecules in the system
available to induce oxidative damage.

5.7 Conclusions
HSA is a very large protein with a molecular weight of approximately 68kDa and a
sequence containing 585 amino acid residues. One of the primary functions of HSA is
to transport fatty acids of varying length, so it is reasonable to presume that the
structure of the protein would be very flexible in order to accommodate the small
molecules it transports. This flexibility added to the difficulty of interpreting the binding
data of DAUDA and DNS to aldehyde-modified HSA.
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Puzzling results were obtained for fluorescence titrations of modified or unmodified HSA
into DAUDA or DNS and the Scatchard plots that were generated from the titration data.
Looking only at the titration data, one could conclude that incubation with an α,βunsaturated aldehyde resulted in a loss of a DAUDA or DNS binding site because of the
lower maximum fluorescence emission compared to titrations of unmodified HSA.
However, compilation of the titration data into Scatchard plots suggested that there was
no loss of binding sites and the affinity of both sites increased by an order of magnitude
with a lower fluorescence enhancement. Modification could cause a change in the
structure that causes higher affinity DNS binding sites to form. These sites might be
different from the binding sites in unmodified HSA or reflect changes in the conformation
of HSA so it is reasonable that the fluorescence properties of DNS binding would be
different, therefore explaining the emission differences in the titration data. The
formation of new binding sites that have increased affinity is also an interesting result
because increased affinity at the medium-chain fatty acid binding sites would make it
more difficult for HSA to release the fatty acid molecules, preventing the effectiveness of
HSA to act as a transport molecule.

Also complicating the analysis of binding data are differences in the emission spectra of
DAUDA binding fluorescence depending on the source and preparation of HSA used.
All of the modification experiments described by this research were done with fatty acid
free HSA. In vivo, HSA always has bound fatty acids (fatty acid-albumin mole ratio
ranging between 0.1 and 2 [11]) and other small molecules. For this research, it was
necessary to start with the least complicated form of HSA, one free of bound ligands, to
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obtain insight into the properties of HSA following α,β-unsaturated aldehyde
modification. It is important to remember that the conditions studied for this research
are simplified compared to what happens under physiological conditions. Under
physiological conditions, we would expect fatty acids to occupy some of the fatty acid
binding sites. If the predictions about coordination of the carboxylate groups on the fatty
acid to a basic (Lys) residue at the opening of the binding site [9-11] are correct, then
the number of Lysine residues available for modification might be diminished.
Therefore, the susceptibility of HSA to covalent modification in vivo may be less than
that occurring in vitro.

Structural modifications were observed in HSA after modification with an α,βunsaturated aldehyde. The protein fluorescence that resulted from this incubation had
properties identical to the water-soluble fluorescence found in serum samples of elderly
subjects. The fluorescence properties were also the same as those characterized from
the reaction of α,β-unsaturated aldehydes with lysine derivatives. This implies that the
water-soluble fluorescence found in serum samples is in part the result of the reaction of
α,β-unsaturated aldehydes with the lysine residues of HSA. Structural modifications
were also observed as the development of bands on SDS-PAGE gels in the high
molecular weight range (intermolecular cross-links) and a very minor species that
migrated to approximately 83kDa (intramolecular cross-links).

Intriguing results from this research came from the cyanogen bromide digests of 4ONE
modified HSA. These experiments were designed in an attempt to locate the primary
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site of modification by an α,β-unsaturated aldehyde through changes observed in the
HPLC elution profile of CNBr treated HSA. E-2-hexenal induced so many cross-links
that the protein was resistant to CNBr treatment. A change in the elution profile was
observed with 4ONE modified CNBr treated HSA. The new peak in this profile also
contained fluorescence with characteristics identical to those that were observed in the
intact protein. Analysis of the components of the fluorescent peak using MALDI-TOF
MS did not lead to any clear answers as to the origin of the fluorescence. It appears
that the separation of the CNBr fragments is not complete for the unmodified CNBr
treated HSA, causing trace amounts of the fragments to co-elute with each other.
Some of fragment 7 (residues 549 – 585) eluted at the same retention time as the
fluorescent peak in 4ONE modified CNBr treated HSA. However, a molecular weight
that corresponds to fragment 7 was not present in the fluorescent peak. No molecular
weights were detected in the 4ONE modified CNBr treated HSA that were not also
detected in the unmodified CNBr treated HSA. It is possible that one of the minor
components in the 4ONE modified CNBr treated HSA was responsible for the
fluorescence, but because of its low concentration, the intensity of the peak would be
too small for detection.

The third area studied in this research was the effect of α,β-unsaturated aldehyde
modification on the antioxidant ability of HSA. Copper(II) binding to HSA was studied
using isothermal titration calorimetry. HSA lost all ability to bind copper(II) after
modification with E-2-hexenal which is probably one of the effects of the extensive
cross-linking of HSA observed via SDS-PAGE gels after modification with E-2-hexenal.
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Although cross-linking was also observed for 4ONE modified HSA, the extent is not as
great based on the CNBr treatment elution profiles. The loss of copper(II) binding is
also not as extensive as with E-2-hexenal, indicating that some, but not all, of the
copper binding sites are modified. A loss of copper(II) binding sites can be directly
related to an increase in the oxidative damage caused by free copper(II) in the system,
therefore implicating the importance of the antioxidant properties of HSA.

In conclusion, α,β-unsaturated aldehydes do induce modifications in the structure,
function, and antioxidant ability of HSA. The question that remains is to what extent do
the modifications affect the ability of HSA to function as it is intended, as a carrier
protein. Is an additional function of HSA to act as a scavenger for the α,β-unsaturated
aldehydes that are produced as a result of lipid peroxidation to prevent them from
reacting with other species in the system? Is HSA designed to be extremely adaptable
so that it can accommodate scavenging the lipid peroxidation by-products in addition to
acting as a transport protein? The research presented here serves as a springboard for
additional experiments that will give more details about the nature of the modification of
HSA from reaction with α,β-unsaturated aldehydes.
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Chapter 6: Future Directions

6.1 Background
The research presented here describes the first research documenting the effects of
α,β-unsaturated aldehydes produced from lipid peroxidation on human serum albumin.
Evidence of structural and functional modification has been observed primarily as the
development of protein fluorescence, changes in DAUDA and DNS binding,
development of higher molecular weight species on SDS-PAGE gels, differences in the
elution profile of modified versus unmodified CNBr treated HSA, and the loss of the
copper(II) binding site as determined by isothermal titration calorimetry experiments.

This project originated as an attempt to characterize the water-soluble fluorescence that
was observed in serum samples of elderly subjects. Presumably, water-soluble
fluorescence develops with age as a result of the accumulation of α,β-unsaturated
aldehydes produced from lipid peroxidation. The fluorescence that was observed in the
serum samples had similar characteristics to those of lipofiscion and ceroid and was
also similar to those observed from modification of HSA with an α,β-unsaturated
aldehyde. Experiments were devised in order to more carefully characterize the
fluorescence that developed and to determine how these modifications affect the ability
of HSA to function as a transport protein.

As with most research, unforeseen complications added to the project and caused
diversions from the intended progression of the research. HSA has proven to be a very
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complicated protein. Part of the complicated nature of HSA might be due to this
protein’s function: transport of a wide range of substances throughout the system. The
three-dimensional structure of HSA can change either by binding fatty acids or through
modification by α,β-unsaturated aldehydes. It has not yet been determined the exact
number or location of the fatty acid binding sites on HSA. Therefore, it is reasonable to
assume that the structure of HSA is flexible and adaptable enough not to have static
binding sites. As one substance binds, the structure of HSA could change slightly
creating additional binding sites. Based on the results presented here, it is reasonable
to ask the question, is one of the functions of HSA to be a “sink” that scavenges byproducts of lipid peroxidation to prevent them from causing damage in the system? If
this were the case, is it also reasonable that HSA was designed with a flexible structure
so that even with lipid peroxidation by-product modification, new fatty acid binding sites
are formed in order for HSA to continue to transport fatty acids throughout the system?
Although the research done up to this point was not as clear cut as originally intended,
intriguing results have been obtained. These results have shed light on other avenues
that could lead to potentially interesting results.

6.2 Future Experiments
Because so much of the research presented herein suggests that there is a
conformational change in HSA upon modification by α,β-unsaturated aldehydes, it
would be advantageous to study the conformational changes of HSA with molecular
dynamics. A few groups have used molecular dynamics to investigate the binding of
various ligands to sites on HSA [1-3]. In addition, conformational changes HSA could
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also be studied using circular dichroism. It would be interesting to design time course
experiments where the change in tertiary structure of HSA induced by incubation with a
lipid peroxidation by-product could be followed using circular dichroism.

One of the most intriguing results presented here was the fluorescent peak from 4ONE
modified CNBr treated HSA. It is obvious that a modification has occurred, however,
the mass spectrometry results did not give any clear explanations about the location of
modification and the CNBr fragments that were cross-linked in order to produce the
fluorescent species. It would be interesting to increase the concentration of 4ONE that
modifies HSA in order to maximize the modification. The fragments would then be
separated and the elution profiles compared to try and determine the location of
modification. 4ONE modification produces a large quantum yield of fluorescence
emission. By increasing the concentration of 4ONE, the fluorescence would be
increased and the modification maximized so that the mass of the fluorescent species
could be more easily determined by mass spectrometry.

Cyanogen bromide was initially used to cleave HSA because it would result in seven
polypeptides of varying length. Producing a small number of fragments would simplify
the analysis of the fragment’s origin. Other proteases could be used to cleave HSA at
different residues, producing a large number of fragments. Producing more fragments
would complicate the analysis but could lead to the possibility of determining more
information about the location of modification of HSA by α,β-unsaturated aldehydes.
Possible proteases include, but are not limited to, Trypsin that cleaves at C-terminal of
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Lys and Arg, Chymotrypsin that cleaves at the C-terminal end of Phe, Trp, and Tyr or
Pepsin that cleaves at the N-terminal end of Phe, Trp, and Tyr. After digestion with a
protease, the peptides could be separated and masses of the polypeptides could be
determined with mass spectrometry. Hopefully, a difference in the fragments of
unmodified versus aldehyde-modified digested fragments would be apparent, indicating
the primary target for modification.

If a single site of modification could be determined, it would then be interesting to
replace the residues subject to modification with a residue that would not be capable of
aldehyde-modification. This would give insight into the adaptability of HSA. If the same
rates of protein fluorescence development were observed, then we would know that
HSA is capable of adapting in order to continue to scavenge the free aldehydes in the
system. If protein fluorescence ceased to develop with amino acid substitution, then we
could say that there are only specific sites of α,β-unsaturated aldehyde modification on
HSA and could compare these sites to the location of known HSA binding sites to
determine potential physiological effects of modification.

An alternate way to investigate the residues involved in cross-linking would be to design
a series of experiments using peptides including Lysine residues separated by varying
distances. The peptides would be incubated with α,β-unsaturated aldehydes and the
time course and kinetics of fluorescence development could be followed. These
experiments would give insight to the correlation between Lysine residue distance and
time of protein fluorescence development.
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Another interesting set of experiments would be to determine the effect that α,βunsaturated aldehydes would have in the presence of HSA and an enzyme. Several
groups have determined the effects of α,β-unsaturated aldehydes on a variety of
enzymes [4-7]. These groups have monitored the loss of enzyme activity upon the
presence of an α,β-unsaturated aldehyde. Because a modification of both HSA and a
loss of enzymatic function have been observed separately with α,β-unsaturated
aldehydes, it would be interesting to see if the aldehyde had a modification preference
when both enzymes and HSA were present. If HSA acts as a scavenger for 4ONE, we
would not expect to see a loss of enzyme activity. No loss of enzyme activity would
also suggest that another function of HSA is to give the α,β-unsaturated aldehydes a
place to react without compromising enzymatic function. This would give insight into the
theory that HSA acts as a sink by scavenging α,β-unsaturated aldehydes in an attempt
to protect other species in the system from modification.

All experiments done up to this point have shed some light onto the effects α,βunsaturated aldehydes have on HSA. More work is needed before a complete picture
of the effects of modification on HSA by α,β-unsaturated aldehydes can be determined.
Through the research presented here and the ideas that have been discussed for future
experiments in this area, it is my hope that new and exciting knowledge will continue to
be gained about the biochemical effects of lipid peroxidation by-products on protein
structure and function.
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